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Aptamers are single stranded DNA or RNA oligonucleotides which are able to interact with their 
designated target molecules with high affinity and specificity. The in-vitro procedure used for 
aptamer selection from a randomly designed oligonucleotide library is named Systematic Evolution 
of Ligands by EXponential enrichment (SELEX). Since aptamers, in comparison to antibodies,  bind to 
larger surface structures, these molecules have the potential to better discriminate between the 
enzymatically inactive zymogen and active enzymes. Indeed, it has been previously shown that a 
DNA-aptamer selected against activated protein C (APC) possesses a high selectivity over zymogenic 
protein C. 
APC is a serine protease which is generated from zymogenic protein C by thrombin-mediated 
proteolytic activation on the surface of endothelial cells. APC performs its anticoagulant activity by 
proteolytic inactivation of activated factors V (FVa) and VIII (FVIIIa) which act as procoagulant 
cofactors within the blood coagulation cascade. Besides its anticoagulant functions, APC shows anti-
inflammatory and anti-apoptotic activities which lead to endothelial barrier stabilization. Mild and 
moderate forms of inherited PC-deficiency predispose patients to an increased risk of venous 
thromboembolism while severe forms are associated with the development of purpura fulminans, a 
severe and potentially life-threatening thromboinflammatory disease comparable to severe sepsis. In 
severe sepsis acquired PC-deficiency plays a central role in the development of microvascular 
thrombosis leading to multiorgan failure. Substitution of septic patients with plasma-purified PC or a 
recombinant version of APC has been shown to improve outcome in terms of mortality rates. An 
increased incidence of bleedings, however, restricted the substitution of APC in patients with 
septicemia. Recombinant APC variants with impaired anticoagulant activity but intact cytoprotective 
properties are potentially safer drugs for the treatment of severe septicemia. Alternatively, specific 
ligands that selectively inhibit the anticoagulant activity of APC might offer several advantages over 
genetically engineered APC-variants. 
To increase the probability to select distinct APC binding sequences with divergent functional 
activities we used a capillary electrophoresis (CE)-based SELEX strategy. In addition different 
randomized ssDNA-libraries were applied, including a G-rich library to increase the likelihood of 
selecting G-quadruplex containing aptamers. The SELEX technology was further improved by 
developing a novel method for single-stranded DNA (ssDNA) production, allowing the convenient and 
rapid purification of ssDNA. 
A previously identified consensus motif dominated the selected aptamer pools despite using two 
differently structured randomized DNA-libraries during CE-SELEX. However, a G-quadruplex forming 
sequence raised up when using a G-rich DNA-library. Evaluation of the impact of identified aptamers 
on the amidolytic activity of APC combined with competition experiments using heparin as 
competitor revealed the so-called basic exosite of APC, which mediates its anticoagulant functions, 
as exclusive binding site. Further functional analysis clarified that, despite sharing the same binding 
site, different aptamers alter the functions of APC in different ways. Most interestingly, the G-
quadruplex-based aptamer protected APC from inactivation by plasma protein C inhibitor while the 
other APC-specific aptamers rather accelerated this process.  
To conclude, the described aptamers may be useful for fast and efficient inhibition of APC under 
APC-mediated bleeding situations. Since the anti-apoptotic and anti-inflammatory functions of APC 
are most likely not influenced by aptamer-binding, such aptamers may be used as an adjuvant 
therapy in hemophilia in which APC inhibition might at least partially compensate the absence or 
reduced activity of FVIII or FIX. Furthermore, the availability of specific ligands with high 
discriminatory power between the zymogenic and active form of APC might be useful for the 
quantification of the active enzyme in biological fluids. 
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1.1. Blood coagulation system 
The occurrence of vascular injury requires rapid clot formation in order to prevent 
hemorrhage. In the case of damaged endothelium, platelets adhere to the sub-
endothelium and, subsequent to instantaneous activation of the haemostatic system, 
fibrin production occurs, which forms a mesh over the platelet plug, sealing the site of 
injury. The explosive activation of the haemostatic system is due to the so-called ‘cascade’ 
system of coagulation in which inactive zymogens and cofactors are sequentially 
activated by proteolytic cleavage 1.  
The coagulation cascade, which was proposed for the first time in 1964, is explainable as 
a model consisting of the interlinked so-called intrinsic and extrinsic pathways (Figure 
1.1).   
The physiologically more important extrinsic pathway involves tissue factor (TF) and 
factor VII (FVII). Upon vascular injury, cells expressing membrane-bound tissue factor 
come into contact with activated factor VII (FVIIa) within the blood. The resulting TF-FVIIa 
complex, as a potent activator of the coagulation cascade, activates two substrates, 
namely, factor IX (FIX) and factor X (FX) 1,2. In turn, activated factor X (FXa) activates 
minute amounts of prothrombin to thrombin 3.  
Thrombin is the key enzyme of the coagulation system due to its biologically important 
functions such as platelet activation, fibrinogen conversion to fibrin, and feedback 
amplification of the plasmatic coagulation cascade. Indeed, thrombin activates the 
coagulation co-factors VIII and V. Activated FVIII (FVIIIa) serves as a cofactor of FIXa within 
the ‘tenase’ complex, which is a contraction of "ten" and the suffix "-ase". This means 
that the substrate FX gets activated through cleavage by the complex. Accordingly, 
together with FXa, activated FV (FVa) forms the prothrombinase complex which activates 
prothrombin to thrombin 1,4. 
At the final stage of the coagulation cascade, fibrinogen is converted by the act of 
thrombin to insoluble fibrin. The multi-step procedure starts with thrombin cleavage of 
fibrinogen to form soluble fibrin monomers. The newly formed fibrin mesh is stabilized by 
cross-linking catalysed through action of thrombin-activated coagulation factor XIII (FXIII) 
1.  
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The currently reputed model of in vivo coagulation agrees on the central role of tissue 
factor as the main coagulation initiator. As described above, this model asserts the rapid 
amplification of thrombin as an essential step in the development of a stable clot and the 
dependence of the model on coagulation factors and cellular elements 2. On the other 
hand, however, activation of the intrinsic pathway involves activation of factor XII (FXII) at 
negatively-charged surfaces exposed to the blood stream due to endothelial injuries. In 
the further course, activated FXII (FXIIa) activates Factor XI (FXI) which in turn activates 
FIX, closing the link between both, the extrinsic and intrinsic pathways 2.  
 
 
Figure 1.1.  The cascade model of coagulation with its intrinsic and extrinsic pathways. C1-inh : 
C1-inhibitor. TF : tissue factor. TFPI : tissue factor pathway inhibitor. AT : antithrombin, modified 
from Norris, 2003 1.  
1.2. Regulation of the coagulation system 
The rapid and efficient activation of blood coagulation is essential to avoid blood loss. 
However, to prevent a generalized activation of coagulation and excess fibrin deposition, 
local and transient activation of the system at the site of vascular injury is required. To 
achieve this goal, various regulatory mechanisms are exerted either by enzymatic 
inhibition or by modulation of the activity of the cofactors. 
As described above, the TF-VIIa complex as a potent initiator of the extrinsic pathway 
activates both, FIX and FX. A specific inhibitor of this complex is named the tissue factor 
pathway inhibitor (TFPI). TFPI is a multi-domain protein which is released from 
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endothelial cells and megakaryocytes and binds to the TF-VIIa complex subsequent to 
binding to FXa 5. The anticoagulant activity of TFPI reduces intravascular procoagulant 
activity in the very early stage and thereby down-regulates thrombin formation 6. 
Many of the activated coagulation enzymes are inhibited by the serine-protease inhibitor 
antithrombin, which mainly forms irreversible complexes with FXa and thrombin. At this, 
the inactivation of free thrombin and FXa by antithrombin occurs faster than that of 
thrombin and FXa bound to activation complexes which ensures the clearance of active 
enzymes from circulation and restriction of their activity to the site of vascular injury and 
corresponding clot formation 1. Heparin and heparin-like molecules from the endothelial 
cell surface stimulate the activity of antithrombin towards both enzymes 5. 
Another important system for the regulation of blood coagulation is the protein C (PC) 
anticoagulant pathway.  
1.3. Activated protein C  
1.3.1. APC structure  
Protein C is a vitamin K-dependent plasma protein which was purified for the first time 
from bovine plasma as described by Stenflo in 1976 7. APC is generated from zymogenic 
protein C by thrombin-mediated proteolytic activation 8. 
Thrombomodulin (TM), which is expressed on the vascular endothelium, forms a 1:1 
complex with thrombin which in turn activates PC bound to endothelial protein C 
receptor (EPCR) on the surface of endothelial cells. Circulatory APC is consisting of a light- 
and heavy-chain molecule held together by a single disulfide bond. The anticoagulant 
activity of APC is directed through irreversible proteolytic inactivation of FVa and  FVIIIa, 
thereby inhibiting further thrombin generation 9.  
Human PC consists of 419 amino acids and undergoes post-translational modifications 
including ß-hydroxylation at Asp71, N-linked glycosylation at residues 97, 248, 313 and 329 
and gamma-carboxylation of nine glutamic acid residues in the amino terminus, the so 
called Gla domain 10.  
Thrombin cleavage of the zymogen PC at Arg169 leads to elimination of the activation 
peptide (residues 158–169) and APC generation. The interaction of APC with different 
plasmatic and cellular proteins are directed by various amino acids embedded in domains 
termed exosites that are distinct from the active site triad consisting of His211, Asp257 and 
Ser360 that is characteristic for all coagulation enzymes 8. The so-called basic exosite, 
consisting of the 37-loop, the 60-loop, and the 70–80-loop is involved in the proteolytic 
inactivation of factors Va and VIIIa 11,12. Furthermore, a negatively charged exosite, which 
consists of acidic residues of the 162 helix is responsible for the interaction of APC with 
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protease activated receptor-1 (PAR-1), mediating the anti-apoptotic and anti-
inflammatory properties of APC 13 (Figure 1.2). 
 
Figure 1.2. Space-filling model of the APC. The basic exosite consisting of basic residues of the 39-
loop, the 60-loop, and the 70–80-loop are presented in red, while acidic residues of the 162 helix 
are exposed in blue. The green part located in the center of the molecule belongs to the catalytic 
triad. This model is configured based on the 1AUT structure from the crystal structure of APC 
deposited in the Protein Data Bank 13. 
 
 
1.3.2. APC anticoagulant activity 
APC performs its anticoagulant activity by irreversible proteolytic inactivation of activated 
FVa/ FVIIIa. The two cleavages responsible for FVa inactivation by APC occur at Arg306 and 
Arg506 in a sequential order including the first rapid cleavage at the Arg506 site followed by 
a slower cleavage at the Arg306 site 12. The exact mechanism by which APC inactivates FVa 
is unclear but according to the findings of some experiments, the main structures of APC 
that take part in cleavage of the Arg506 site are the 39-loop (Lys37-Lys39) and the 70-80–
loop (particularly Arg74 and Arg75) 14. In the presence of protein S (PS), the cleavage of 
Arg306 is accelerated by 20-fold and the presence of FXa protects FVa from inactivation by 
APC through selective blockage of the Arg506 cleavage site 15. 
APC-mediated inactivation of FVIIIa takes place at the homologous sites Arg336 and Arg562, 
located on the A1 and A2 subunits, respectively. Tendency for cleavage site selectivity is 
directed by the presence of other coagulation factors. While FIXa inhibits cleavage at the 
A2 site (Arg562), FX protects FVIIIa from inactivation through cleavage at the A1 site 
(Arg336) 16. Unlike FVa, a cleavage on each of the cleavage sites leads to almost complete 
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inactivation of FVIIIa. Protein S (PS) enhances the cleavage rate at the Arg562 site 
approximately 5 fold, however, it has only a moderate effect towards the Arg336 site 11.  
FV promotes inactivation of FVIIIa by acting in synergy with PS as a cofactor of APC in the 
inhibition of the FVIIIa - FIXa complex. A mutant form of FV known as FVLeiden, is less 
susceptible to proteolysis by APC due to amino acid substitution at Arg506 and the 
mutated FV does not display this anticoagulant cofactor activity. Since  cleavage at Arg506  
of FV by APC is prerequisite for its cofactor function, FV-Leiden has a 10-fold less 
efficiency as an APC-cofactor in the degradation of FVIIIa 17. It has been also described by 
Castoldi et al. that the procoagulant effects of the FVLeiden mutation is not only due to 
insensitivity of FVa to APC-mediated proteolysis but also to the loss of the above 
mentioned APC cofactor activity 18. 
Although the APC-mediated FVIIIa inactivation was confirmed in several investigations, 
spontaneous dissociation of A2 domain of FVIIIa might be the primary mechanism of 
FVIIIa inactivation due to the short plasmatic half-life of FVIIIa (~ 2 min) 
19. 
1.3.3. APC  cytoprotective activity 
APC cytoprotective activities include anti-inflammatory activity, anti-apoptotic activity 
and protection of the endothelial barrier. These cytoprotective effects mostly require the 
two receptors EPCR and protease activated receptor-1 (PAR-1).   
The APC anti-inflammatory effect can be conveyed into the effect on endothelial cells and 
the effect on leukocytes. APC inhibits the release of inflammatory mediators from 
leukocytes and endothelial cells and down-regulates vascular adhesion molecules, leading 
to reduced leukocyte adhesion and tissue infiltration and, consequently, decreasing 
damage to the tissue 20. 
Breakdown of the monolayer of endothelial cells which separates the blood from 
underlying tissue plays a key role in inflammatory processes such as sepsis. APC enhances 
the endothelial barrier integrity by binding to EPCR and activation of PAR-1, leading to 
subsequent inhibition of inflammatory gene expression in endothelial cells 21. In animal 
and human studies, APC proved to inhibit endotoxin-induced pulmonary injury and 
inflammation due to inhibition of leukocyte accumulation and chemotaxis 22. 
In addition to an improved survival rate in murine endotoxemia models, a large 
randomized clinical trial also suggested the pharmacologically beneficial effects of APC in 
reducing mortality in sepsis 8. The PROWESS trial has urged approval of drotrecogin alfa 
(recombinant human activated protein C, (Xigris®, Eli Lilly) by the Food and Drug 
administration (FDA) in the clinical treatment of adults suffering from severe sepsis in the 
last quarter of 2001 23. However, subsequent studies in 2010 showed a lack of efficiency 
of APC in septic shock treatment and an increased incidence of bleeding. As a result, it 
was withdrawn from the market 24,25. The increased incidence of bleedings was related to 
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the anticoagulant activity of APC as conducted by the basic exosite apart from the 
cytoprotective related exosite.  
According to the above described findings that the anticoagulant and anti-inflammatory 
effects of APC are directed by distinct subdomains 26, the increased incidence of bleeding 
that encompassed the use of Xigris® may be controllable by the use of APC-specific 
inhibitors which affect the anticoagulant activity of APC while cytoprotective effects 
remain active. Furthermore, a specific ligand which interferes with the anticoagulant 
activity of APC might be helpful as an adjuvant therapy in hemophilia patients to 
compensate the lack of FVIII. In addition, having a specific ligand which could bind to APC 
with high affinity might be helpful in promoting diagnostic test systems to capture and 
detect the level and activity of APC in biological fluids. In this regard, aptamers represent 
a potent alternative to conventional antibodies. 
1.4. Aptamers 
Aptamers (from the Latin aptus - fit, and Greek meros - part) are oligonucleotide or 
peptide molecules which can bind to their target with high affinity and specificity 27. 
Nucleic acid aptamers (aptamers) are single-stranded DNA (ssDNA) or RNA 
oligonucleotides which can shape to specific three-dimensional structures including 
stems, loops, or G-quadruplexes 28. Based on their 3D structures, aptamers are able to 
bind to various molecular targets such as small molecules, proteins, nucleic acids, and 
even whole cells 29. The folding of the nucleic acid provides numerous interactions 
depending on the ligand which is responsible for aptamer-target binding such as 
electrostatic bonding, van der waals interactions, hydrogen bonding, base stacking effects 
and hydrophobicity or combination of these bindings 30. For protein targets, the aptamer 
binding site is mostly on the surface of the target whereby non-covalent interactions lead 
to maximum binding through optimum complementarities 29. 
The binding affinity of aptamers varies from the low nanomolar range for larger target 
molecules such as proteins to the micromolar range for small chemicals. A high selectivity 
of aptamers for their targets was described in many publications. In aptamers selected 
against coagulation factors, an active form-selectivity has been observed 13. Moreover, 
the so-called enantiomer-selectivity which refers to the discriminatory power of an 
aptamer between two enantiomer molecules was also reported for aptamers 31. 
Aptamers not only show comparable binding affinity for their target molecules, but also 
offer advantages over antibodies as they can readily be produced by chemical synthesis 
which reduces batch to batch variation, and show adequate stability to a wide range of 
pH and organic solvents 32. Modification of aptamers may lead to increased stability in 
biological fluids or binding enhancement 33. Some modifications specific for RNA 
aptamers such as changing of the 2´-OH groups of ribose to 2´-F or 2´-NH2 groups or 2´-O-
methyl substituted nucleotides protect them from nuclease degradation 34. A 3´-end 
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capping such as inverted thymidine (3´-idT) or making a 3´-3´ linkage as well as executing 
5´-caps by amine, phosphate or polyethyleneglycol (PEG) protect oligonucleotides from 
exonucleases 35,36.  
1.4.1. Aptamer selection procedure 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX), which was described 
for the first time on 1990 27,37 is a technology for in vitro selection of high affinity nucleic 
acid aptamers recognizing a designated target molecule 28. SELEX consists of repetitive 
cycles of selection, partitioning and amplification of binding sequences to enrich specific 
sequences with reasonable binding affinity. Normally the procedure starts with a nucleic 
acid library which consists of a random region flanked by two primer binding sites 
necessary for the amplification step. Through incubation of the random library with the 
target molecules, by chance, some sequences are able to bind to the target molecules. 
These specific sequences will be eluted from the target molecules after the partitioning 
step and amplified by a PCR reaction. The partitioning step is the most crucial step of the 
SELEX procedure. This step, in which the strong binding DNA-molecules are separated 
from unbound or weakly bound sequences, may influence the yield of selection, also due 
to the potential contamination of bound sequences with unspecific oligonucleotides 
(Figure 1.3). 
Depending on the used DNA or RNA library for selection, a reverse transcription step is 
needed to transcribe RNA oligonucleotides to DNA strands which are necessary for the 
amplification process. The resulting double-stranded DNA has to be transformed into a 
new oligonucleotide pool by separating the relevant ssDNA or by in vitro transcription 
and subsequent purification of the synthesized RNA. This new pool of selected single-
stranded oligonucleotides is used for incubation with the target molecules in the next 
round of SELEX 28. Generally 8 to 12 selection cycles are needed to reach to high affinity 
aptamers. As assessed by measurement of the crude binding affinity, the enriched final 
pool will be subjected to the cloning and sequencing step to identify individual aptamers. 
Representative aptamer-clones are then chosen and used in binding assays to 
characterize their binding features in terms of affinity and specificity. 
Sequence truncation for identifying the minimal binding motif is an important step to 
narrow down the critical binding domains. As assessed by predicted 2D structures, 
redundant regions are removed, and the properties such as binding affinity or specificity 
of the truncated aptamer checked. 




Figure 1.3. Schematic representation of DNA aptamer selection. The starting point of each SELEX 
procedure is incubation of a synthetic random DNA oligonucleotide library with target molecules 
followed by repetition of the iterative steps of selection, amplification and preparation of single-
stranded DNA. In the selection step, binding sequences are partitioned from unbound and/or 
weakly bound oligonucleotides. The target-bound oligonucleotides are eluted and subsequently 
amplified by PCR. A new enriched pool of selected oligonucleotides is generated by preparation of 
the relevant ssDNA from the PCR products. This new enriched pool is used for the next SELEX 
round. Generally, 6 to 20 SELEX rounds are required for the selection of high affinity, target-
specific aptamers. Assessment of the enrichment of target specific oligonucleotides indicates the 
plateau of the SELEX procedure and the enriched library is subjected to cloning and sequencing to 
obtain individual aptamers.  
 
1.4.2. Capillary electrophoresis (CE) 
Electrophoresis involves an electrical field to attract or repulse the ingredients of a 
mixture in an electric field. It was introduced as a separation technique by Tiselius in 1937 
and led to the Nobel Prize in chemistry in 1948 38. Primary application of open tubes for 
electrophoresis was described by Hjertén in 1967 which continued in the early 1980s 
Chapter 1: General introduction and outline 
10 
 
using fused silica capillaries by Jorgenson and Lukacs 39. Electrophoresis inside a capillary 
not only brings about the advantages of performing electrophoresis in free solution but 
also reduces the detrimental effects of Joule heating. Furthermore, due to the high 
electrical resistance of the capillaries, high electrical field applications (100 to 500 V/cm) 
are operational which in turn provide short analysis times and high efficiency and 
resolution of separation 38,39. 
Another advantage of capillary electrophoresis is its instrumental simplicity. Briefly, as 
shown in Figure 1.4, both ends of a capillary column, as well as two electrodes providing 
electrical contact to a high voltage power supply, are placed in buffer reservoirs. The 
sample can be injected into the capillary through two different injection modes: 
Hydrodynamic injection or Electrokinetic injection. In hydrodynamic injection, which is 
the most common used injection technique, an applied pressure or vacuum for a certain 
period of time introduces the sample into the capillary column. In electrokinetic injection, 
an applied current or voltage causes the sample to migrate into the capillary column. This 
kind of injection is frequently applied for highly viscose materials 40. 
 
Figure 1.4. Diagram of capillary electrophoresis system. (A) The capillary electrophoresis system 
consists of a capillary column expanded between source and destination vial, both containing 
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electrophoresis buffer. The sample is injected into the capillary column and separated under high 
voltage applied to both ends of the capillary column. (B) In fused-silica capillaries, positively 
charged buffer ions are attracted to the negatively charged silanoate groups (Si-O-). This forms 
two inner layers of cations. Under the high voltage applied between the ends of the capillary, the 
more mobile layer which is distant from the silanoate groups moves in the direction of the 
negatively charged electrode, resulting in a constant bulk flow of electrolytes called the 
electroosmotic flow (EOF). Although the EOF is always toward the electrode having the same 
charge as the capillary wall, positively charged molecules move faster due to the electrophoretic 
attraction to the negatively charged electrode while negatively charged molecules are retained 
longer because of their contradictory electrophoretic mobility. Therefore, molecules are 
separated by mass/charge ratio within the flow.  
 
In fused-silica capillaries, silanol groups (Si-OH) which are attached to the interior wall of 
the capillary, are ionized through a first conditioning step using alkaline solution like KOH 
or NaOH. The silanoate groups (Si-O-) attract positively charged buffer ions to form two 
inner layers of cations, called the diffuse double layer. Under the high voltage applied 
between the ends of the capillary, the outer layer which is distant from the silanoate 
groups and therefore more mobile, moves in the direction of the negatively charged 
electrode, resulting in a constant bulk flow of electrolytes called the electroosmotic flow 
(EOF). This EOF represents the main trigger responsible for the mobility of injected 
materials within the capillary. Due to the greater force of the EOF than the 
electrophoretic mobility of the compounds, all injected molecules migrate from the inlet 
(anode) to the outlet (cathode) of the capillary 38. As a result of the electrophoretic 
attraction to the negatively charged electrode, positively charged molecules move faster 
while negatively charged molecules are retained longer because of their contradictory 
electrophoretic mobility. Therefore, depending on its mass and charge, each specific 
molecule possesses a specific retention time under the conditions defined by the 
electrophoresis setup 39. 
1.4.3. Capillary Electrophoresis-based SELEX (CE-SELEX) 
Conventional SELEX normally involves the immobilization of the target protein. Despite 
the advantages accompanied with immobilized targets such as efficient partitioning of 
bonded sequences from non-binders, some draw backs such as the need of so called 
counter selection to exclude sequences that show cross-reactivity to the applied solid 
support has to be mentioned. Another disadvantage of target immobilization may be the 
masking of specific structures which may affect the selection. Thus, homogenous 
selection methodologies such as capillary electrophoresis-based SELEX (CE-SELEX), which 
allows the selection of aptamers against free targets are an advantage and also provide a 
high resolving power that reduces the desirable number of cycles for selection to 4 to 6 
cycles instead of 8 to 12 cycles when using conventional selection schemes 41,42. 
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Potential disadvantages of CE-SELEX are the limitation of the sample volume which leads 
to restriction of the total number of ssDNA-molecues that can be introduced into the 
capillary, the difficulty of selecting aptamers against basic or low molecular weight target 
molecules, or thermal band broadening of CE because of Joule heating which restricts the 
ion composition of the partitioning buffer 39. Furthermore, the optimal conditions must 
be determined for each individual protein, randomized library and selection buffer 41,43. 
During the first step of CE-SELEX, a randomized ssDNA-library is incubated with the target 
molecule in free solution. After a certain incubation time, the mixture containing free 
target molecules, target-ssDNA complexes and free ssDNA is injected into a primed 
capillary. The loaded capillary is placed to span two reaction tubes filled with neutral to 
basic conductive buffer. In the case of the replacement of the negatively charged 
electrode in the end of the capillary, the positively charged free target proteins migrate 
faster while the negatively charged non-bound library retains longer within the capillary. 
Collecting the outlet fraction at the retention time specific for target-bound ssDNA offers 
the opportunity of gathering target-binding DNA-aptamers. 
Collected sequences are then amplified and generated single-strands subjected to the 
next round of the selection procedure. Usually 4 to 6 cycles of selection are required for 
the enrichment of an aptamer-pool showing peak bulk binding affinity. Subsequent 
analysis of included single aptamer-sequences by either cloning/sanger-sequencing or 
next-generation sequencing approaches finally leads to the identification of candidate 
sequences to be tested for binding affinity and specificity.  
1.5. Single-stranded DNA production 
After partitioning step of SELEX procedure, the enriched pool is subjected to the PCR 
amplification to increase the copy number of specific sequences. Double strand 
sequences resulted from PCR amplification could not introduced to the next selection 
cycle before single strand production has been performed. 
Several procedures has been described indicating single strand production from double 
strand PCR products such as alkaline-based denaturation of biotinylated PCR-products 
after immobilization onto streptavidin-coated magnetic beads (SMB) or enzymatic strand 
digestion after asymmetric PCR 44,45. Apparently, all of these procedures do accompany 
with their advantages and drawbacks. For example, alkaline-based treatment requires 
final neutralization or solvent exchange of the final product to achieve suitable ssDNA for 
proceeding with the next selection cycle.   
Biotin streptavidin separation including alkaline treatment is another rapid and efficient 
method in which PCR amplified double strands are immobilized onto SMBs using 
biotinylated forward or reverse primer followed by separation of desired non-biotinylated 
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strand from immobilized biotinylated one using alkaline treatment (NaOH). Further steps 
such as ethanol precipitation can increase ssDNA concentration. The posibility of 
releasing of biotinylated non-target strand and/or streptavidin due to the alkaline 
treatment is the major drawback of this method which results to loss of tertiary structure 
of specific strand due to re-anealing of complementary strand or introduction of a 
secondary target for selection, respectively 45,46.  
Lambda exonuclease selectively digests phosphorylated strand from 5’ to 3’ end with high 
affinity to phosphorylated 5’end rather than the hydroxylated 5’ end. The procedure is 
fast and efficient however, subsequent purifications such as phenol/chloroform 
extraction for lambda exonuclease elimination results in reduction in the yield of ssDNA 
production 45.  
Recently, we introduced a novel fast and convenient principle for the purification of 
ssDNA named Capture and Release (CaR) which has been described extensively in chapter 
3 47. Briefly, short biotinylated oligodeoxynucleotides, that are complementary to the 3’-
end of the target single stranded oligodeoxynucleotides (aptamers), are bound to 
streptavidin magnetic beads. Incubation of the loaded streptavidin magnetic beads with 
asymmetric PCR mixtures results in capturing of the ssDNA which can be easily released 
after washing by alteration of temperature and ion strength conditions (Figure 1.5). 
 
Figure 1.5. Principle of capture and release (CaR) procedure. Single-stranded DNA (ssDNA) is 
captured from crude assymetric PCR mixture using streptavidin magnetic beads (SMBs) loaded 
with short biotinilated DNA molecules complementary to the 3’ end of the ssDNA. Captured 
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ssDNA is released after washing by increasing the temperature and lower the ion strength 
conditions. 
1.6. Aptamers against coagulation factors 
Anticoagulation is an important therapeutic strategy for the prevention and treatment of 
thrombotic disorders. 
Heparin, is widely used as a parenteral antithrombotic due to its low cost and ease of 
monitoring. However, numerous shortcomings accompany heparin as it bears the risk of 
hemorrhage and heparin-induced thrombocytopenia 48. Warfarin, a member of the 
vitamin K antagonists, is an oral anticoagulant with a narrow therapeutic window and 
requires individualized dosing based on the international normalized ratio (INR). Due to 
the narrow therapeutic index and necessity for frequent laboratory monitoring associated 
with warfarin, there has been a desire for the development of new and effective 
anticoagulants. Among novel anticoagulants (NACs) direct thrombin and FXa inhibitors 
were designed. Some of these direct thrombin inhibitors are administered parenterally, 
including argatroban and bivalirudin; however, oral administration of dabigatran 
increases patient compliance in long term use. Having idarucizumab (Praxbind®) in hand 
as a monoclonal antibody designed for the reversal of anticoagulant effects is another 
advantage of dabigatran.  
Also direct acting factor Xa inhibitors are used for prophylaxis and/or treatment of 
embolic diseases. Andexanet-alpha which is a modified recombinant derivative of FXa, 
acts as an antidote for direct inhibitors of factor Xa including  apixaban, rivaroxaban and 
edoxaban 49,50. Lack of specific laboratory parameters available to monitor the 
anticoagulant impact is a major drawback of FXa inhibitors 51. Conventional coagulation 
monitoring assays such as activated partial thromboplastin time (aPTT) and prothrombin 
time (PT) are unable to accurately measure the degree of anticoagulation in patients 
undergoing therapy with NACs. Therefore, management of bleeding complication mostly 
comprises basic principles of bleeding management, including rapid assessment of the 
source, cause, and severity of bleeding, cessation of anticoagulation therapy and, if 
possible, reversal of anticoagulation effects, using specific antidote 52,53. 
To overcome the major drawbacks of NACs, an optimal anti-thrombotic drug which is 
safe, non-toxic and well adjustable is needed. Other optimal characteristics that might 
accompany with an anti-thrombotic drug are rapid onset of action, predictable dose-
response, selectivity for a specific biological target and reversible action 54. Among 
different researches for finding reasonable novel candidate molecules, aptamers appear 
as an emerging class of future anticoagulants. Chemical modifications of aptamers such as 
amino- or fluoro- modification at the 2’ position of pyrimidines as well as 3’ inverted 
deoxythimidine caps make RNA aptamers resistance to nuclease degradation. 
Conjugation of polyethylene glycol and other moieties lead to the reduction in aptamer 
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renal clearance during in vivo utilization. The general concept of antidote control of 
aptamers relies on Watson-Crick base pairing which alter the 3D structure of the aptamer, 
leading to loss of target binding affinity 55. On the other hand, aptamers can be used as 
capturing ligands to quantify the circulating level of certain coagulation factors in plasma 
as well as other biological fluids. For example, the application of an oligonucleotide 
(aptamer)-based enzyme capture assay (OECA) allows rapid quantification of circulating 
levels of APC under pathological conditions such as hip-replacement surgery. The test 
platform quantifies the activity of aptamer-captured APC through hydrolysis rates of a 
fluorogenic peptide substrate 56. 
Several aptamers have been selected against different coagulation factors such as 
thrombin, activated protein C, FVIIa and FIXa (Table 1.1). 
Table 1.1. Binding properties and application of selected aptamers against blood coagulation 
proteins  
 
Target Oligo type Binding 
affinity 
[nM] 
Binding site Application Reference 
Human α-
thrombin 
DNA ~ 200 Fibrinogen 








RNA 9.3 Heparin binding 






DNA 0.5 Heparin binding 








RNA 0.65 EGF1 and/or 
EGF2 domain of 
FIX 




VWF DNA ˃20 GPIbα binding 
domain on vWF 








2 nM*  GPIbα binding 
domain on vWF 
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APC DNA 0.47 Heparin binding 
site 




* The binding affinity has been determined for A1 domain of VWF 
 
1.6.1. Thrombin binding aptamers 
The first DNA-aptamer against thrombin has been selected in 1992 by Bock et al 57. This 
aptamer, which was named later as HD1, interferes with thrombin catalyzed conversion 
of fibrinogen to fibrin. The structure of the aptamer, which was solved by structural 
analysis, is an antiparallel G-quadruplex and conducts it to one of the anion binding site of 
thrombin, named exosite I. The second thrombin-recognizing aptamer, which possesses a 
RNA structure, was selected two years later by Kubik and colleagues 58. Another DNA 
based thrombin binding aptamer which bears a G-quadruplex structure and binds to the 
heparin binding exosite of thrombin, known as exosite II, was identified by the same 
group 59. Later on, a bivalent aptamer consisting of the two DNA aptamers coupled via a 
poly- dA linker has been described as the most potent aptameric thrombin inhibitor. It 
binds to both anionic exosites without blocking the active site of the enzyme 65. This 
bivalent aptamer, HD1-22, has been used for the measurement of plasma thrombin 
levels. Through incubation of primed plasma samples in microtiter plates pre-coated with 
HD1-22, thrombin is captured and detected using a thrombin-specific fluorogenic peptide 
substrate. Compared to the available thrombin measurment techniques, which are based 
on the measurment of thrombin-antithrombin complexes (TAT) or prothrombin activation 
peptides (F1.2) as two cumulative markers in plasma, using an aptamer-based capturing 
assay for direct measurement of circulating levels of active thrombin better reflects the 
real time coagulation status 66. 
1.6.2. Factor IXa binding aptamer 
An aptamer specific for FIXa has been described in 2002 by Rusconi et al 60. This RNA 
aptamer, which is reinforced against nucleases by using 2'-fluoropyrimidines, was 
assessed in both in vitro and in vivo studies. The binding site and the impact of the 
aptamer on blockade of intrinsic and extrinsic coagulation pathways are controversially 
discussed. Although Rusconi et al. have an impression that the FIXa aptamer blocks either 
intrinsic or extrinsic pathway probably through binding protease and EGF2 domains of 
factor IXa, later experiment conducted by Gopinath et al. revealed that this aptamer 
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specifically blocks the extrinsic coagulation pathway with emphasizing on binding domain 
of the Gla and EGF1 domains on factor IXa 67. Rusconi et al also reported the binding site 
of EGF2 domain on FIXa for aptamer 60. The concept of using a complementary 
oligonucleotide as an aptamer-specific antidote was first described for the FIXa aptamer 
(Figure 1.5) and currently assessed in clinical trials. REG1 (Regado Biosciences) is an anti-
FIXa aptamer system containing the aptamer pegnivacogin (RB006) and anivamersen 
(RB007) in which RB007, the complementary oligonucleotide antidote, binds to RB006 by 
Watson-Crick base pairing and neutralizes its anti-FIXa activity 68. In a phase 1a study after 
intravenous injection of RB006 in healthy volunteers and in phase 1b study demonstrating 
the efficiency of RB006 as well as the-RB007 antidote in patients with stable coronary 
artery disease, no major bleeding or any other serious adverse events were observed 69,70. 
A subsequent phase 2a clinical trial demonstrated the effectiveness of the REG1 system 
when combined with platelet-directed therapy in patients suffering from stable cardiac 
artery disease (CAD), while a phase 2b (RADAR) study revealed the effectiveness of RB006 
in patients with acute coronary syndrom (ACS) undergoing cardiac catheterization 71. A 
randomized multicenter phase 3 trial planned to randomly allocate 13200 patients 
undergoing percutaneous coronary intervention and to compare the effectiveness of the 
REG1 system to bivalirudin faced early termination with 3232 patients due to severe 
allergic reaction in 1% of patients receiving REG1. Thus, according to the limited events 
and low statistical power resulting from the premature termination of the study, there 
was no evidence that using the REG1 system reduces ischaemic events or bleedings when 
compared to bivalirudin 72. 
 
 
Figure 1.5. The REG1 anticoagulation system which is composed of the anti-FIXa aptamer 
pegnivacogin (RB006) and the oligonucleotide antidote to RB006, anivamersen (RB007). Antidote 
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RB007 and the motif within RB006 which pairs to RB007 shown in red. P indicates polyethylene 
glycol; idT, inverted deoxythymidine; modified from Nimjee et al., 2006 73.  
 
1.6.3. Anti-vWF aptamers 
ARC-1172 is a DNA-aptamer recognizing von-Willebrand factor (vWF). The aptamer can 
strongly inhibit vWF-mediated platelet adhesion due to inhibition of the vWF A1-domain 
and platelet GPIbα membrane receptor interaction. Furthermore, by using specific 
antidote molecules, platelet functions could be efficiently restored 61. Later on, ARC-1779, 
a DNA/RNA-based aptamer was introduced. The molecule included a 5’- conjugation of 
PEG while the aptamer still showed high binding affinity to A1 domain of vWF 63. The first 
phase 1 clinical trial which investigated safety, pharmacokinetics and pharmacodynamics 
of the aptamer in healthy volunteers started in 2007 and was successfully completed in 
the same year (NCT00432770) (http://clinicaltrials.gov). Then, the next evaluation study 
suggested dose- and concentration-dependent inhibition of vWF activity and platelet 
function of ARC1779 without a significant increase in bleeding 74. In a phase 2 clinical trial 
started in 2008 in 36 patients undergoing carotid endarterectomy (CEA), intravenous 
injection of the aptamer was effective in reducing cerebral embolism 75. To conclude, 
between the years 2007 and 2010, among six registered clinical trials considering phase 1 
and 2 clinical trials of ARC-1779, one had been withdrawn and three phase 2 trials have 
been terminated due to the reason that the enrollment into studies was slower than 
expected. 
1.6.4. Anti-APC aptamers 
The first aptamer selected against APC was described in 1998 64. The non-modified RNA 
aptamer consisted of 167 nucleotides and showed an intermediate binding affinity to APC 
(KD = ~ 100 nM). However, the selectivity of the aptamer over zymogenic protein C was 
not evaluated. In 2009, the selection of DNA aptamers against APC was described. The 
aptamers showed enhanced affinity for APC in the subnanomolar range and a 200- to 
400-fold lower binding affinity to PC 13. According to the fact that DNA aptamers are 
fundamentally more resistant to enzymatic degradation in the plasma or whole-blood 
matrix compared to non-chemically modified RNA aptamers, a longer half-life in these 
matrices can be expected. Using the truncated aptamer variant HS02-52G, an 
oligonucleotide-based enzyme capture assay (OECA) was developed and validated. The 
assay allows the measurement of APC plasma levels under clinical conditions with a lower 
limit of detection of 22 pg/mL (0.4 pM) 56. Furthermore, HS02-52G aptamer binds to basic 
exosite of APC without affecting the anti-apoptotic and cytoprotective functions of the 
active enzyme. Thus the selective inhibition of the anticoagulant activity of APC offers a 
potential application of HS02-52G to stop APC-induced bleeding complications in patients 
receiving recombinant APC. 
Chapter 1: General introduction and outline 
19 
 
1.7. Aims and outlines of the thesis 
Aptamers are single-stranded DNA or RNA molecules which bind to their designated 
target molecules with high affinity and specificity. The ease of production and reduced 
batch to batch variability make aptamers interesting diagnostic tools as well as clinically 
applicable agents. Enzymes involved in the blood coagulation process are multi task 
proteins containing several functional domains. Activated protein C (APC) is a serine 
protease with plasmatic and cellular functions. Beside its role in inactivation of FVa and 
FVIIIa, it has cytoprotective effects which include anti-inflammatory and anti-apoptotic 
activities. The interactions of APC with FVa and FVIIIa are directed by the so-called basic 
exosite while the acidic exosite is involved in the interaction with protease activated 
receptor-1 (PAR-1), mediating the anti-apoptotic and anti-inflammatory properties of 
APC. Interference with each domain may lead to alteration of enzyme functions either by 
steric hindrance or allosteric inhibition.  
The aim of this study was first to identify aptamers that specifically recognize APC and 
then to elucidate the effect of these aptamers on the different functions of APC.  
The first priority to achieve aptamers that possess a high binding affinity is to set up a 
selection method accompanied with high efficiency and resolution of separation. To 
accomplish this goal, CE-SELEX was performed which accompanied with numerous 
advantages such as using target proteins in native free conformation and a high resolving 
power which leads to higher conversion rate of specific sequences in shorter time. 
Consecutive steps of a selection procedure as well as the evaluation of the binding affinity 
of selected aptamers to APC are described in chapter 2.  
Single-stranded DNA production is a crucial step during the aptamer selection procedure 
in order to provide an enriched library of aptamers needed for the next selection round.  
Accordingly, in chapter 3, a convenient and rapid method for ssDNA production named 
Capture and Release (CaR) that allows direct isolation and concentration of ssDNA from 
asymetric PCR-mixtures without the need for post-processing and conditioning steps is 
introduced. This method is described in the context of the CE-SELEX procedure but may 
also be implemented in other applications that require the generation of ssDNA. 
Due to the fact that different functions of APC such as anticoagulant and cytoprotective 
effects are directed by distinct exosites, selective modulation of APC functions might be 
aplicable according to the binding site of each specific ligand. Furthermore, as aptamers, 
in comparison to antibodies, bind to larger surface structures, binding of aptamers to the 
same or overlaping regions might cause distinct effects on the anticoagulant function of 
APC. Accordingly, in chapter 4 the selection and characterization of DNA-aptamers 
against APC using the established CE-SELEX and CaR methods is described. In addition a 
comprehensive functional characterization of the newly identified APC-aptamers has 
been performed. The found aptamer-mediated alterations of the anticoagulant functions 
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of APC opens the horizon in the prevention of APC-induced bleeding such as in trauma-
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Capillary electrophoresis-based SELEX (CE-SELEX) is an efficient technique for the isolation 
of aptamers binding to a wide range of target molecules. CE-SELEX has a number of 
advantages over conventional SELEX procedures such as the selection of aptamers can be 
performed on non-immobilized targets, usually within a fewer number of selection cycles. 
Here we describe a complete procedure of CE-SELEX using activated protein C (APC) as 
the target protein. 
2.2. Introduction  
Aptamers are single stranded DNA or RNA molecules which are able to bind to different 
target molecules ranging from small organic molecules to entire organisms. Aptamers are 
typically selected from randomized libraries of nucleic acids using a procedure termed 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX) which was introduced 
for the first time in 1990 27,37. The SELEX-procedure consists of multiple rounds of 
selection, partitioning and amplification which are repeated to allow for the enrichment 
of aptamers with high binding affinity. This procedure will be completed by cloning 
and/or sequencing, and evaluation of individual aptamer sequences 76. 
During conventional SELEX, targets need to be immobilized onto solid supports to allow 
for efficient separation from non-binding ssDNA-molecules. However, further 
progressions led to the development of homogenous methods, such as capillary 
electrophoresis (CE)-SELEX, which allow the selection of aptamers against free targets 77.  
In CE-SELEX, the random library is incubated with the target molecules in free solution 
and then the mixture containing free target molecules, target-ssDNA complexes and free 
ssDNA is injected into a capillary column and separated under high voltage. Collecting the 
outlet fraction at the retention time specific for target-bond ssDNA brings about the 
opportunity of gathering target-binding DNA-aptamers. 
Besides homogeneous conditions, this kind of selection has additional advantages such as 
a high resolving power that reduces the number of cycles needed for selection to 4 to 6 
cycles instead of 8 to 12 cycles when using conventional selection schemes 42. However, 
also potential disadvantages do accompany CE-SELEX such as limitation in the total 
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number of ssDNA-molecues introduced to the capillary or the difficulty of selecting 
aptamers against basic or low molecular weight target molecules 43. 
In this chapter, a protocol for CE-SELEX of DNA-aptamers against activated Protein C 
(APC) is described. Although elucidated for the use of a ProteomeLab PA 800 System 
(Beckman Coulter, Krefeld, Germany), the described principles are also applicable when 
using other CE-systems. 
2.3. Materials 
2.3.1. Capillary electrophoresis 
1. Proteomelab TM PA 800 capillary electrophoresis (Beckman Coulter, Inc., Fullerton, 
CA, USA) equipped with UV/PDA detector. 
2. Bare fused-silica capillary, 67 cm total length, 50 cm effective length, 50 µm inner 
diameter (i.D.), 375 µm outer diameter (o.D.) (Beckman Coulter, Inc. Brea, CA, 
USA). 
3. Plastic vials, 0.5 ml. 
4. Glass vials, 2 ml and caps (Beckman Coulter, Inc. Brea, CA, USA).   
5. Random ssDNA-library IHT1: 5’- AAG CAG TGG TAA GTA GGT TGA - N40 - TCT CTT 
CGA GCA ATC CAC AC -3’. Order 1 µmol synthesis scale followed by PAGE 
purification. Store lyophilized powder at 2-8°C until dissolved. Aliquot and store 
resolved stock solutions (e.g. 100 µM) at < -20°C until used. 
6. Separation buffer: 25 mM Tris-HCl, 10 mM NaCl, 1 mM KCl, 1 mM CaCl2  and  1 
mM MgCl2 , pH 8.3 (see Note 1) (see Note 2). 
7. Human activated protein C (APC) (e.g. Haematologic Technologies, Essex Juction, 
Vermont, USA). Store stock solutions as indicated on label until used (see Note 3).  
8. Vivaspin®6 centrifugal concentrators with 10,000 Da MW cut-off (Sartorius 
Stedim, Goettingen, Germany). 
9. Washing buffers: 0.1 N NaOH; 0.1 N HCl; ultrapure water. 
2.3.2. Polymerase chain reaction (PCR) 
1. Thermal cycler. 
2. HotStarTaq Plus DNA polymerase including buffers.  
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3. Amplification primers targeting the fixed sequences of the library in full length, 
HPLC purified. Store lyophilized powder at 2-8 °C until dissolved. Aliquot and store 
resolved stock solutions (e.g. 100 µM) at < -20°C until used.   
4. Deoxynucleotide triphosphates solution, 25 mM of each. Aliquote and store stock 
solutions at -20°C until used. 
5. PCR tubes 0.2 ml. 
2.3.3. Agarose gel 
1. LE Agarose.  
2. Tris Borate-EDTA buffer: 50 mM Tris, 45 mM boric acid, and 0.5 mM EDTA, pH 8.4. 
3. 10 mg/mL Ethidium bromide. Aliquot and store stock solutions. Add adequate 
amount of ethidium bromide to agarose cooled to 50-60°C to reach a final 
concentration of 0.5 µg/ml (see Note 4). 
4. DNA molecular weight marker XIII, 50 base pair ladder. 
5. Loading buffer for gel electrophoresis: 40% succrose, 0.1% Xylene cyanol and 0.1% 
Bromophenol blue. Store stock solutions at 4-8°C until used. 
2.3.4. ssDNA production 
1. NanoDrop® ND-1000 UV/Vis-Spectrophotometer (Thermo Scientific). 
2. Thermomixer. 
3. Magnetic beads separator. 
4. Streptavidin-coated magnetic beads (SMB), Dynabeads M-280 Streptavidin (Life 
Technologies, Karlsruhe, Germany). Store the vial upright to keep the beads in 
liquid suspension since drying of the beads will result in reduced performance. 
Store the vial at 2-8°C, avoid freezing. 
5. 5’ -biotinylated capture molecules, complementary to a part of the 3’ primer-
binding section of the IHT1 library: 5’-Biotin-GTG TGG ATT GC-3’. Store lyophilized 
powder at 2-8°C until dissolved. Aliquot and store resolved stock solutions (e.g. 
100 µM) at  -20°C until used. 
6. Binding and washing buffer 1 (B&W 1): 5 mM Tris-HCl, 1 M NaCl, 0.5 mM EDTA, pH 
7.5. 
7. Binding and washing buffer 2 (B&W 2): 5 mM Tris-HCl, 1 M NaCl, pH 7.5. 
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8. Washing buffer: 10 mM Tris-HCl, 20 mM NaCl, pH 7.5. 
9. 5 M NaCl-solution. 
10.  Protease-free bovine serum albumin (BSA). Store at 4°C. 
11.  SMBs storage buffer: 1x PBS, 0.1% BSA, 0.02% NaN3 , pH 7.4.  
2.3.5. Filter retention analysis 
1. Phosphorimager. 
2. Dot-Blot system, e.g. Minifold® I Blotting System (Whatman, USA).  
3. T4 polynucleotide kinase. 
4. Phosphorimager screen and matching cassette. 
5. γ-32P ATP (PerkinElmer, Rodgau, Germany). 
6. Dulbecco's phosphate buffered saline containing 0.5 mM MgCl2  0.9 mM CaCl2. 
7. Illustra microspin G-25 columns. 
8. Nitrocellulose membranes, 0.45 μm pore size. 
9. Yeast tRNA, 10 mg/ml. 
2.4. Methods 
During the first step of CE-SELEX, the randomized library is incubated with the target 
molecule (e.g. APC). After incubation, a small volume of the sample is injected into a 
primed, silica-fused capillary for CE-based separation of non-binding from target-bound 
sequences. The loaded capillary is then placed to span two reaction tubes filled with 
neutral to basic conductive buffer solution. During separation under high voltage applied 
between the tubes, positively-charged buffer ions that are attracted to the negatively 
charged surface of the capillary do migrate to the cathodic end, resulting in a constant 
bulk flow of electrolytes that is called the electroosmotic flow (EOF) and represents the 
main trigger responsible for the mobility of injected materials within the capillary. 
Because the force of the EOF is greater than the electrophoretic mobility of the 
compounds, all injected molecules migrate from the inlet (anodic) to the outlet (cathodic) 
of the capillary 38. Due to the electrophoretic attraction the positively charged molecules 
move faster while negatively charged molecules are retained longer because of their 
contradictory electrophoretic mobilities. Therefore, depending on its mass and charge, 
each specific molecule possesses a specific retention time under the conditions defined 
by the electrophoresis setup 39. The negatively-charged ssDNA sequences which show 
binding affinity to the faster moving target protein molecules migrate at retention times 
that are shorter than that of the bulk non-binding ssDNA-library molecules. Thus, target-
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binding sequences can be collected from the outlet of the capillary within the so-called 
collection window that is the time between the start of the separation and the time that 
unbound sequences reach the outlet. 
Collected sequences are amplified and generated single-strands introduced to the next 
round of the above described CE-SELEX-procedure. Usually 4 to 6 cycles of selection are 
required for the enrichment of an aptamer-pool showing peak bulk binding affinity. 
Subsequent analysis of included single aptamer-sequences by either cloning/Sanger-
sequencing or next-generation sequencing approaches finally leads to the definition of 
candidate sequences to be tested for binding affinity by filter retention analysis.  
Due to the lower amount of ssDNA that is injected into the capillary, in comparison to 
other selection methods, an increased risk of contamination with non-target-specific 
sequences stemming  from capillary and/ or instrument contaminations must be 
considered. The most critical source of contamination are the unbound library-sequences 
which migrate in spatial proximity to the desired specific aptameric sequences. As the 
amount of the specific sequences is trivial when compared to the bulk library sequences, 
contamination of the outlet of the capillary with non-binding sequences obvioulsy 
reduces selection efficiency. Another source of contamination are the PCR-products from 
previous rounds of selection. Thus, rigorous separation of pre- and post-PCR areas as well 
as pre- and post-PCR materials is needed to avoid potential contaminations of evolved 
pools with previous-generation sequences.        
Within the following sections, the main general procedures for the selection of DNA-
aptamers against APC by CE-SELEX are described. Please consult the manual of the used 
CE-system / software for specific technical details.    
2.4.1. Installation and conditioning of a new capillary 
Install a new capillary for each individual selection. The following points describe the most 
critical steps during installation and use of a new capillary when running the Beckman 
Coulter PA 800 System. 
1. Remove seal retainer clips as well as the aperture plug and the O-ring form the 
cartridge. Firmly remove the used capillary by pulling it out from the cartridge 
inlet side. Insert the new capillary into the outlet side of the cartridge with the end 
utmost from the capillary detection window (near to the cartridge window). 
2. Push the capillary carefully into the cartridge base until it appears at the inlet. 
Protect detection window of the capillary from breakage (see Note 5). 
3. Once the end of the capillary appeares in the inlet side of the cartridge, pull it 
from the inlet side until the detection window appears centered within the 
cartridge window. 
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4. Insert the capillary seal clips over the capillary at both inlet and outlet side. Use 
the Capillary Length Template to accordingly cut both ends of the capillary using 
the cleavage stone. In doing so, adjust the ends of the capillary to be one 
millimeter shorter than the electrodes within the final CE-Cartridge assembly. 
Then re-install the aperture plug and O-ring.  
5. Check the capillary ends under magnification and re-cut/ re-adjust the capillary in 
case of angled or denticulated ends.  
6. Condition the capillary before the first use. For silica-fused capillaries, use the 
conditioning program described below: 
Reagent Presseure Voltage Duration 
NaOH, 0.1 M 20 psi ---- 4 min 
Air drying 20 psi ---- 2 min 
ddH2O 20 psi ---- 2 min 
Separation buffer 20 psi ---- 4 min 




2.4.2. CE-based isolation of target-binding ssDNA-molecules 
2.4.2.1. Incubation of ssDNA-library and APC  
1. Dilute the starting library in separation buffer to yield a concentration of 25 µM in 
final volume of 20 µl (see Note 6). Use a final concentration of 0.5 µM of selected 
ssDNA pools during the subsequent cycles (see Note 7).  
2. Heat the thus diluted library to 90°C for 5 min using one single PCR tube and let it 
to return to the room temperature to allow for proper folding the random ssDNA-
molecules. 
3. Centrifuge the PCR tube shortly. 
4. Spike the APC target-protein into the ssDNA pool to reach the final concentration 
of 0.5 µM for the first cycle and incubate the mixture for 30 min at RT (see Note 8) 
(see Note 9).   
2.4.2.2. Injection into capillary and separation of components under EOF  
1. Wash both ends of capillary and electrodes with destilled water and dry it using 
cotton swabs. 
2. Place the single PCR tube containing target-ssDNA-mixture in injection site and 
prepare assembly needed for sample injection.  
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3. Add 100 µl of separation buffer each into tubes that will be defined and used as 
the inlet and outlet buffer vials during separation. 
4. Adjust the separation temperature for the capillary to 20°C. 
5. Perform separation using a program as described below (see Note 10): 
Step Reagent Presseure Voltage Duration Mode of action 
1 Target protein-
ssDNA mixture 
4 psi- inlet ---- 5s Hydrodynamic 
Injection (see Note 
11) (see Note 12) 











Separation with the 
positive electrode 
at the inlet 
4 End 
1 
Performing constant voltage should supply constant current during separation (see Note 13). 
2 Duration of separation depends on the retention time of the unbound fraction of ssDNA. 
Separation must be stop before the unbound ssDNA start to migrate out of the capillary. 
Determine collection window before start of the actual process for CE-SELEX (see Note 14). 
6. Remove the collected fraction vial with caution using a new pair of gloves and close  
cap immediately as any contamination with non-binders will reduce the efficiency 
of selection. 
2.4.2.3. Washing process between the runs 
As the separation procedure stops before the migration of unbound sequences out of the 
capillary, a precise washing step is required to remove the unboound sequences from the 
capillary while protecting the instrument as well as the surronding area from 
contamination by unspecific sequences (see Note 15). 
1. Use the 0.5 ml plastic vials and buffer trays for washing step (see Note 16). 
2. Clean the blue vial caps with destilled water and with aid of syringe.   
3. Try to fill the vials starting from the bottom to avoid air bubbles. 
4. All vials must be caped before starting the electrophoresis. 
5. Follow the program indicated below: 
Reagent Presseure Voltage Duration Mode of action 
HCl, 0.1M 20 psi ---- 5 min Reverse rinse wash  
NaOH, 0.1M 20 psi ---- 5 min Reverse rinse wash 
ddH2O 20 psi ---- 5 min Reverse rinse wash 
Washing buffer 20 psi ---- 5 min Reverse rinse wash 
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2.4.3. PCR-based amplification of selected ssDNA 
1. Prepare a PCR master mixture containing 0.8 mM dNTPs, 1 mM each forward and 
reverse primer, 1.5 mM MgCl2, 1.25 U/reaction HotStartTaq DNA polymerase and 
20 µl of sample in a total volume of 100 µl. 
2. Amplify collected ssDNA in a total of 5 reactions at 95°C for initial activation of 
HotStartTaq DNA polymerase followed by 30 cycles of 95°C for 30 s, 56°C for 30 s 
and 72°C for 30 s. 
3. Pool all PCR mixtures and check the quality by running 10 µl of PCR product mixed 
with 2 µl of 5x loading buffer on a 2% agarose gel. 
2.4.4. Asymmetric PCR and isolation of ssDNA  
The production of ssDNA is a crucial step of the SELEX-process. This paragraph describes 
the application of ‘Capture and Release’ (CaR) for the isolation of ssDNA from asymmetric 
PCR mixture (see Note 17) 47. During the approach described here, additional asymmetric 
PCR is performed on previously amplified selected ssDNA (see subheading 2.4.3).  
1. Dilute the yielded PCR products (see subheading 2.4.3) 1 in 10 using destilled 
water. 
2. Add 10 µl of the dilution to 10 PCR vials containing 90 µl of asymmetric PCR 
master mixture (prepared as described in subheading 2.4.3 but without addition 
of reverse primers). 
3. Perform reactions in a thermal cycler by applying 50 cycles of the temperature 
profile  described in subheading 2.4.3. Check the quality of ssDNA obtained from 
asymmetric amplification by running a 10 µl sample on a 2% agarose gel. 
4. Resuspend the streptavidin magnetic beads by shaking the vial vigorously and take 
1 mg of the beads (100 µl of 10 mg/ml stock suspention).  
5. Wash the beads three times using B&W 1 buffer and a suitable magnetic device. 
Incubate the beads in 200 µl B&W 1 containing 1 µM of capture molecules (2 µl of 
100 µM stock solution) for 30 min at room temperature. Prevent settling of the 
beads by shaking at 1200 rpm during incubation. 
6. Wash the beads three times using 1 ml of B&W 2.  
7. Pool and add the total of 1 ml of the asymmetric reaction mixtures to the loaded 
SMBs followed by spiking with 5 M NaCl to reach a final concentration of 100 mM.  
8. Incubate for 30 min at room temperature. Prevent setteling of the beads by 
shaking at 1200 rpm during incubation. 
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9. Wash the beads three times using washing buffer.  
10. Add 20 µl of pre-heated purified water to the beads and  incubate for 2 min at 
43°C to release captured ssDNA. Collect supernatant after separation of beads at 
43°C. 
11.  Determine the concentration of obtained ssDNA by nanodrop UV-measurement. 
12. Use isolated ssDNA for the next selection cycle. 
For storage, resuspend the loaded SMBs in storage buffer and store at 4°C until used.  
2.4.5. Filter retention experiment 
1. Add 5 to 10 pmol of purified ssDNA to a master mixture containing 5 µl T4 PNK 
buffer (10x), 2 µl T4 polynucleotide kinase (T4 PNK, 10 U/µl), 2 µl γ-32P ATP (3.3 
µM; 10 µCi/µl) in a final volume of 50 µl. 
2. Incubate the mixture for 30 min at 37°C. 
3. Prepare the G-25 columns by resuspending the resin by vortexing. Twist off the 
bottom closure and centrifuge at 735 x g for 1 min. 
4. Pipett the labeling reaction to the top-center of the resin. Avoid disturbing the 
resin bed (see Note 18). 
5. Purify the labeling reaction by centrifugation at 735 x g for 2 min. Discard used 
G25 column. 
6. Check the removal of unbound radioactivity as well as the integrity of the labeled 
DNA by PAGE-analysis. 
7. Dilute the 32P-labeled DNA 1:10 with 1x D-PBS, heat it up to 90°C for 5 min 
followed by cooling down to room temperature (see Note 19). This temperature 
treatment is necessary for obtaining stable conformation of ssDNA at room 
temperature. 
8. For each aptamer pool or single sequence to be tested, prepare a dilution series of 
the target protein (APC) in D-PBS containing 0.1% BSA and 10 µM yeast t-RNA. 
Pipette 24 µl of each dilution into a single well of a microtiter-plate. Always 
include a buffer-only sample. Run all analysis in at least duplicated. Add 1 µl of 
pre-diluted 32P-labeled to each of the designated wells.     
9. Cover the plate using parafilm and incubate it at 37°C for 30 min. 
10. Soak the nitrocellulose membrane in freshly prepared 0.4 M NaOH followed by 
washing with 1x D-PBS (without BSA and tRNA). 
11. Transfer the pre-treated nitrocellulose membrane into the Dot-Blot system, apply 
the vaccume and wash each well three times using 150 µl of 1x D-PBS. 
12. Use a 8-channel pipette to transfer 20 µl of the incubation mixtures to individual 
wells of the prepared blotting assembly.  
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13. Wash each well three times using 150 µl 1x D-PBS to remove non-target-bound 
sequences. 
14. Remove membrane from the device and allow to air dry. 
15. Pipett 0.8 µl of the used dilution of each applied 32P-labeled DNA onto the same or 
another nitrocellulose membrane. These spots represent the total amount of 
radioactivity (i.e. labeled DNA) that was introduced to each well. Cover 
membranes by using a thin plastic foil, assemble with screen and close cassette 
(see Note 20).  
16. Scan screen using the phosphorimager and quantify the single dots relative to the 
corresponding 100% spots. (Figure 2.1).  
17. Use 4-parametric regression analysis for calculation of KD-values. Sigmoidal curve 
patterns are needed to yield reliable results.    
 
Figure 2.1. Example of Dot-Blot images for the assessment of pool binding affinities over 
performed selection cycles. For testing of the starting random library, the indicated APC-
concentrations were applied in a transposed pattern (wells 3 to 14). The 100% spots were 
arranged in accordance with the according to the applied sample wells. The shown data revealed 
highest percentage of binding and affinity of the aptamer pool gathered after five cycles of 
selection.         
 
2.5. Notes 
1. All buffers should be prepared in ultrapure water using analytical grade reagents. 
Buffers should be filtered before use as present particles may interfere with 
proper electroosmotic flow or even plug the used capillary. 
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2. The composition of the buffer and the salt concentration can be varried according 
to the selection conditions. The current set by a certain voltage is a function of salt 
concentration in the separation buffer. However, exceeding more than the 
maximum tolerated current (300 mA) can harm the interface block of the 
instrument. 
3. As changing of the compositon of the used selection buffer can not only interfere 
with aptamer-binding but also produce fluctuations in the electropherogram, we 
strongly recommend to change the buffer of the used APC using Vivaspin®6 
concentrators by three consequtive addition of the separation buffer in the same 
volume as introduced APC followed by centrifugation at 2000 g in 4°C. The 
resulting APC concentration might be determined using NanoDrop® ND-1000 
UV/Vis-Spectrophotometer regarding to the APC extinction coefficient of 
𝐸1 𝑐𝑚,   280𝑛𝑚
1% = 14.5. 
4. The major drawback of ethidium bromide is its mutagenic potential. When used, 
ethidium bromide solution should therefore be handled with caution.   
5. Always use gloves while installing a new capillary as finger print reduces detection 
sensitivity in capillary window. Handle the capillary with caution as the detection 
window is fragile. 
6. No peak in electropherogram might be a sign of an air bubble at the bottom of the 
sample vial or insufficient quantity of sample in sample microvial. In these cases, 
remove the air bubble or increase the sample volume up to 100 µl, respectively.  
7. The concentration of random library has a significant impact on the initial number 
of unique sequences introduced to the target and the capillary. Due to the 
presence of multiple copies of binding sequences after the first selection cycles, a 
reduced concentration of ssDNA (e.g. 0.5 µM) during the consecutive selection 
cycles will not affect the efficiency of the selection.  
8. Injection of a sample with a different salt concentration than that of the separation 
buffer produces fluctuation in baseline of the electropherogram. Therefore, 
ensure that the incubation mixture of the ssDNA and the target protein 
corresponds to the composition of the selection buffer. 
9. Gradually reduce the protein concentration with each selection cycle. It has been 
previously shown that the efficiency of enrichment of best binders is directed by 
the stringency of the selection that is increased by reduction of the protein 
concentration 78. As the target concentration decreases, the presence of high 
affinty aptamers in the collected pool increases while the considerable point is the 
practical lower limit which means that once the target protein concentration 
drops below the kd value of the aptamer with highest binding affinity, further 
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decreasing in the protein concentration has no significant or only a slight impact 
on further enrichment 79. 
10. Under a certain condition applied to the capillary and by using the same buffer 
system, each target protein, bound fraction of the library- target protein and 
unbound ssDNA migrate at a certain time. In case of APC as the target protein, 
determination of the collection window required separate injections of protein 
and library in order to assess individual retention times (Figure 2.2). In our 
opinion, collection of target-binding sequences should be already stopped when 
the bulk library sequences become detectable by UV-measurements. 
 
Figure 2.2. Determination of aptamer collection window. Electropherograms obtained from 
separate injections (4 psi, 5 seconds) of the IHT1 random library (25 µM) with UV detection at 254 
nm and activated protein C (2 µM) with UV detection at 214 nm (inlet).  
 
11. There are two different posibilities for samples injection: 1) Hydrodynamic 
injection 2) Electrokinetic injection. In hydrodynamic injection, an applied pressure 
for a certain time introduces the sample to the capillary column which is known as 
the most frequently used injection technique. In electrokinetic injection, an 
applied current or voltage for a certain time causes the sample to migrate into the 
capillary column. This kind of injection is mostly applied for high viscosity 
materials which is not common in CE-SELEX 40. 
12. The volume of the sample introduced to the capillary (𝑉𝑖𝑛𝑗) by hydrodynamic 
injection  is a function of the capillary inner diameter, the viscosity of the buffer, 
the applied presure and injection time. The loaded volume can be calculated using 
the Hagen-Poiseuille equation 39: 
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∆P = pressure difference across the capillary 
d = capillary inside diameter 
tinj = injection time 
η = buffer viscosity 
L = total capillary length 
13. Low or unsteady current might be an indicator of a plugged capillary. One solution 
is to rinse the capillary with ddH2O at 100 psi for 10 min. Change the capillary to a 
new one in case the problem persists 80. 
14. As the retention time indicated in an electropherogram is the migration time of 
the define compound to the detection window but not to the end of the capillary, 
the exact time at which each compound reaches to the end of the capillary can be 
calculated using equation below: 




𝑙𝐷: Capillary length to the detector or effective length 
𝑙𝐸: Capillary length from detection window to the end (which for beckman coulter PA 
800 capillaries is constant to 10.2 cm) 
𝑡𝑚: Migration time of the defined compound to the detection window 
 
15. Contamination of collected fractions with unspecific sequences should be 
considered in SELEX procedures using capillary electrophoresis. Due to the small 
amount of molecules injected into the capillary, contamination of the outlet with 
the bulk unbound sequences can negatively interfere with the next SELEX cycle. To 
avoid such a huge source of contamination, a strategy that prevents the bulk 
library sequences from reaching the outlet of the capillary is a necessity. 
Therefore, stopping the EOF during retention of the unbound sequences and 
flashing out these unbound sequences via the inlet of the capillary is a reasonable 
measure. 
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16. As the inlet of the capillary always comes into contact with unbound ssDNA at high 
concentrations during injection, it should always be assumed as a source of 
contamintaion. Thus, physical separation of vials/ rubbers used at the inlet or the 
outlet of the capillary is strongly recommened. Furthermore, the use of single-use 
plastic vials instead of glass vials will significantly reduce potential sources of 
contamination.   
17. Capture and Release (CaR) is an efficient procedure for isolation of ssDNA required 
for each selection cycle. Briefly, short biotinylated oligodeoxynucleotides, that are 
complementary to the 3’-end of the target single stranded oligodeoxynucleotides 
produced during asymmetric PCR, are bound to streptavidin magnetic beads. 
Incubation of the loaded streptavidin magnetic beads with asymmetric PCR 
mixtures results in capturing of the ssDNA which can be easily released after 
washing by altering temperature and ion strength conditions 47.  
18. Although the G-25 colums may be applied in conjunction with a fixed-angle rotor, 
we observed much better performance when using a swing-out rotor. 
19. The dilution factor depends on the intensity of radioactivity.  For example, after 
one half life of applied or available radioactivity (14.3 days), the dilution factor 
may be reduced to 1:5. 
20. The incubation time depends on the intensity of the radioactivity that retained on 
the nitrocellulose membrane. For samples freshly labeled with only little decayed 
32P ,incubation for a few hours might be sufficient while low levels of radioactivity 
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Short biotinylated oligodeoxynucleotides immobilized on streptavidin-coated magnetic 
beads allow for convenient and rapid purification of single-stranded 
oligodeoxynucleotides from crude asymmetric PCR mixtures, facilitating the selection of 
DNA aptamers.    
3.2. Main manuscript 
The preparation of single-stranded DNA (ssDNA) after PCR-based amplification is a crucial 
step during the selection of DNA-aptamers, a process also termed as systematic evolution 
of ligands by exponential enrichment (SELEX) 57,81. Currently applied strategies range from 
asymmetric PCR and enzymatic strand digestion to the most commonly used alkaline-
based denaturation of biotinylated PCR-products after immobilization onto streptavidin-
coated magnetic beads (SMB) 44,45,82–84.  
The possibility to directly purify PCR-products even from crude reaction-mixtures might 
be the main reason for the common utilization of the SMB-based method. Separation of 
strands is usually done by alkaline-treatment rather than heat-denaturation, because of 
the massive release of streptavidin into solution at elevated temperatures 45,84. However, 
in this case final neutralization or solvent exchange of the product is required to proceed 
with the selection cycle. Furthermore, due to the strong association between biotin and 
streptavidin, SMBs are usually used once, significantly increasing costs.  
In principle, asymmetric PCR represents the method of choice for direct generation of 
ssDNA, 85 followed by gel-electrophoresis for the selective extraction and purification of 
ssDNA from dsDNA and reaction components 45. Not least due to the short length of 
random libraries used for SELEX (< 100 nts), however, loss of ssDNA during the 
purification processes is high. Moreover, gel components and conceivably applied nucleic-
acid dyes are additional sources of potential contamination 86.  
In order to combine the advantages of asymmetric PCR with SMB-based concentration 
and purification, we established a novel approach, named capture and release (CaR) that 
facilitates purification of ssDNA from crude PCR mixtures. During CaR, short biotinylated 
oligodeoxynucleotides (capture molecules), complementary to a defined site at the 3’-
end of the target-ssDNA are employed. After their immobilization onto SMBs they are 
added to (pooled) crude asymmetric PCR mixtures. During this step the capture molecules 
bind to the target-ssDNA and subsequently the beads are washed and finally taken up in a 
small volume of ultrapure water. Due to the strongly decreased concentration of 
monovalent and magnesium ions, the melting temperature (Tm) of the immobilized 
capture-molecules bound to the targets decreases 87 , allowing the release of pure ssDNA 
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at only moderately increased temperatures, whereby the integrity of the SMBs is 
preserved (Scheme 3.1). 
The CaR method was successfully applied during capillary-electrophoresis (CE)-based 
SELEX (CE-SELEX) 76,88. We employed two distinct ssDNA-libraries (IHT1 and IHT2N) and 
selected aptamers for two different protein targets, namely activated protein C (APC) and 
the activated A-subunit of factor XIII (FXIIIAa), two key enzymes of the coagulation 
cascade 56,89. For the design of corresponding capture molecules, an online tool for the 
prediction of DNA thermodynamics was used 87 (see ESI† for methodological details). As 
shown in Scheme 3.1 (IHT1) and Figure S 3.1 (IHT2N, ESI†), predicted melting 
temperatures between the library- and capture molecules mainly depend on the 
concentration of salt-ions but were also influenced by the concentration of capture 
molecules present during the different steps of CaR. Due to the inevitable presence of 
residual amounts of washing buffer associated with the SMB-pellet and the tube, a 
concentration of 5 mM of monovalent cations was assumed to be present during the final 
release step.    
 
Scheme 3.1. Principle of CaR and predicted melting temperatures of the IHT1-capture molecules 
at different buffer conditions during the different steps. A, Capture; B, Wash; C. Release. Tm-
values represent the melting temperature at which 5% [Tm(05)], 50% [Tm(50)], or 95% [Tm(95)] 
of captured ssDNA molecules are predicted to be released from the capture molecules. 
 
We first assessed the basic functionality of CaR using asymmetrically amplified DNA-
library IHT1 (ESI†). For capturing of ssDNA molecules, 5’-biotinylated IHT1 capture 
molecules were bound to SMB (200 pmole/ mg SMB; Figure S 3.2, ESI†). Subsequently, 
500 µl of pooled crude asymmetric PCR mixtures were added to 1 mg of SMB that were 
loaded with capture-molecules (SMB+). After incubation for 30 min at RT, SMB+ were 
washed and finally resuspended in 20 µl of ultrapure water. The release of captured 
ssDNA was assessed at RT and three elevated temperatures (37°C, 43°C, and 50°C). After 
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two minutes of incubation, SMB+ were separated by magnetic force and supernatants 
collected. Three consecutive elution steps using new batches of water at each 
temperature were conducted (Figure S 3.3, ESI†). 
Comparable yields of ssDNA in the low pmole range (low µM concentrations) were 
released at elevated temperatures with about 90% of the ssDNA being released during 
the first elution step as determined by UV-measurements (Figure 3.1A). Gel analysis and 
A260/A280 ratios revealed high purity of isolated single-strands (Figure S 3.3, ESI†). 
 
Figure 3.1. Key-characteristics of the CaR procedure. Open bars show results of the first elution, 
striped bars: 2nd, gray bars: 3rd. A, Yield of ssDNA at different elution temperatures. B, Prove of 
sequence-specificity. C, Degree of streptavidin-contamination at different elution temperatures. 
D, Leakage of capture molecules from SMB.   
 In order to prove the specificity of CaR, non-loaded SMB or SMB loaded with non-
complementary IHT2N capture molecules were introduced to the described assay with 
captured ssDNA released at 43°C (ESI†). As shown in Figures. 3.1B and S 3.4 (ESI†), only 
the application of SMB+ enabled the isolation of IHT1-ssDNA from crude asymmetric 
reaction mixtures, demonstrating the sequence specificity of the assay.  
To assess the potential rate of contamination of produced ssDNA with streptavidin, 1 mg 
of non-loaded SMB in 20 µl of ultrapure water were incubated for 2 min at RT, 37°C, 43°C, 
50°C, 70°C or 90°C. After the separation of beads, supernatants were tested for the 
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presence of streptavidin-(subunits) (streptavidin) by ELISA (ESI†). Three consecutive 
experiments using the same SMBs were performed at each temperature. As shown in 
Figure 3.1C, even at RT, a detectable amount of streptavidin (~6 fmole [300 pM 
concentration]) leaked from the SMB during the first elution step. Up to a temperature of 
43°C, leakage only marginally increased to a total of ~7 fmole (~350 pM) while a further 
apparently exponential increase in leakage was observed at temperatures of 50°C or 
higher. 
These data demonstrate that the amount of streptavidin contamination depends on the 
elution temperature used, the amount of SMB used, and the total yield of ssDNA. For 
instance, when considering an elution temperature of 43°C and a yield of 20 pmol of 
ssDNA (1 µM concentration), the degree of contamination on a molar basis would be 
0.04% (400 ppm) when using 1 mg of SMB. 
It has been previously described that the interaction between biotin and streptavidin gets 
weakened in non-ionic aqueous solutions in a temperature-dependent manner 46. Thus, 
besides adverse release of streptavidin from the SMB, also the leakage of biotinylated 
capture molecules from streptavidin into solution had to be considered. To study this 
effect, SMB were loaded with 3’-fluorescence-labelled capture molecules (200 pmole/ 
mg) and treated as described for the streptavidin release experiments. The concentration 
of capture molecules in the supernatants was determined by fluorescence measurements 
(ESI†). Indeed, it was found that significant amounts of capture molecules leaked into 
solution. Up to an elution temperature of 43°C, however, leaked amounts were limited to 
a maximum of ~ 2 pmole (100 nM concentration) during the three consecutive 
experiments, corresponding to a loss of ~ 1% of SMB-bound capture molecules per 
incubation (Figure 3.1D). Nevertheless, at a yield of 20 pmole of ssDNA (1 µM 
concentration), the degree of contamination would be up to 10% under these conditions. 
In summary, these results demonstrate that ssDNA prepared by SMB-based CaR will be 
contaminated with streptavidin and biotinylated antisense molecules.  
The contamination of ssDNA-preparations with SMB-derived streptavidin has also been 
described for the, in comparison to heat denaturation, more gentle alkaline (NaOH)-
based denaturation of immobilized PCR-products 83,84,90. For example, Civit et al. achieved 
ssDNA-concentrations of ~ 40 nM while the contaminating concentration of streptavidin, 
as also measured by ELISA, was reported to be ~ 150 pM 
84. This corresponds to ~ 3,750 
ppm, an approximately 10-fold higher rate than observed in the present study. However, 
due to the use of different SMB and/ or different (mainly qualitative) methods for the 
detection of streptavidin in different studies, a more comprehensive comparison of 
contamination rates appears to be difficult. The same is true for the following adverse 
effect. 
Since alkaline conditions also negatively affect the interaction between biotin and 
streptavidin, the NaOH-based denaturation of SMB-bound PCR-products also leads to the 
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contamination of ssDNA with released double-stranded PCR-products and/ or (re-
annealing) complementary strands 45,83. While biotinylated capture molecules exclusively 
bind to their corresponding target-region at the 3’-end of the isolated aptamers. Thus, in 
comparison to NaOH-denaturation of full-length complementary strands, binding of 
released capture molecules will, if at all, lead to considerably lower interference with the 
tertiary structure of the selected aptamers.    
In contrast to the previously described methods for ssDNA-generation, the characteristics 
of CaR determine that potential aptamers that find their 3’end involved in intra-molecular 
folding patterns may not be efficiently captured and therefore be sorted out during 
selection. Indeed, one might argue that, at least during the first cycle of CaR-based SELEX, 
aptamers are not solely selected for target binding but also with respect to proper 
annealing to the applied capture molecules. Due to the presence of high overall sequence 
diversity at coincidently high frequency of identical or similar sequence patterns during 
the first selection cycles, however, this appears to be more of a fact than a problem.    
Using the IHT1 and IHT2N ssDNA libraries, asymmetric PCR/ CaR was applied during CE-
SELEX to obtain DNA-aptamers recognizing activated protein C (APC) and the activated A-
subunit of factor XIII (FXIIIAa) 56,89. Since APC was used successfully during previous 
selections 64, this enzyme was mainly considered as a model target for evaluation 
purposes. In contrast, the selection of aptamers against FXIIIAa has not been described so 
far. In total, 6 selection cycles were performed during 3 independent selections (APC 
targeted by IHT1 and IHT2N, FXIIIAa targeted by IHT1, ESI†). The yield and purity of ssDNA 
obtained during the different cycles of IHT1- and IHT2N-based selections was found to be 
comparable (Tables S 3.1- S 3.3, ESI†). After selection, the starting- and enriched libraries 
were radioactively labelled in order to (i) sensitively assess the purity of prepared ssDNA 
by PAGE and (ii) to determine the binding affinity by filter retention analysis (ESI†).  
As shown in Figures. 3.2A and 3.2B, distinct bands as determined by denaturing PAGE 
confirmed the high quality of CaR-prepared ssDNA. More importantly, filter retention 
analysis revealed successful enrichment of DNA aptamers by CaR-SELEX binding to APC or 
FXIIIAa. Highest apparent binding affinities of gathered pools were obtained after 4 to 6 
cycles of selection (Figures. 3.2C and 3.2D).  




Figure 3.2. Quality of CaR-produced ssDNA (aptamers) and target binding patterns. A, B, PAGE 
analysis of radioactively labelled original IHT1 and IHT2N libraries and aptamer pools obtained 
after 1 to 6 selection cycles (A, APC-SELEX; B, FXIIIAa-SELEX). Different background levels on the 
screen on the left were caused by an artefact during exposure. C, D, Filter retention analysis. C, 
Percentage of binding of IHT1- (open bars) and IHT2N- (closed bars) derived aptamer pools to 
APC (100 nM). D, Binding of IHT1-derived aptamer pools to FXIIIAa (100 nM). 
 
Cloning and sequencing of the selected aptamers led to the identification of individual 
sequence clones from which ssDNA was produced by CaR (Figure S 3.5, ESI†) and tested 
by filter retention analysis. As shown in Figure S 3.6 (ESI†), determined binding affinities 
of all individual sequences were within the high picomolar to low nanomolar range. As 
expected, in silico two-dimensional DNA folding analysis indicated that the 30-ends of 
found aptamers are accessible to the used capture molecules (Fig. S 3.7, ESI†).    
Having shown the usefulness of CaR during aptamer selection and single clone ssDNA-
production, we next focused on the reusability of the applied SMB+ for ssDNA-
production. For this purpose, asymmetrically amplified ssDNA (clone #1 of the IHT1-based 
selection against APC, Figure S 3.5, ESI†) was pooled and aliquotes of 500 µl each 
introduced to repetitive CaR using the same batch of SMB+ (ESI†). As shown in Figure S 
3.8 and Table S 3.4 (ESI†), comparable yields of highly pure ssDNA were achieved during 
four consecutive experiments. 
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In conclusion, we introduced a novel fast and convenient method for the purification of 
ssDNA. In contrast to previously described applications, CaR allows isolation and 
concentration of ssDNA from crude reaction mixtures in a single tube without the need 
for any post-processing steps like pH-adjustment or sample purification. Thus, we believe 
that, not least due to its scalable nature, the combination of asymmetric PCR and CaR will 
also be implemented in other applications that require the generation of ssDNA in the 
future. 
3.3. Electronic supplementary information ( ESI†) 
3.3.1. Chemicals and reagents 
Protease-free bovine serum albumin (BSA), biotin-labelled BSA, rabbit whole antiserum 
against streptavidin, and all general chemicals were purchased from Sigma-Aldrich 
(Taufkirchen, Germany). HRP-labelled goat anti-rabbit antibodies were purchased from 
Dako (Hamburg, Germany). Streptavidin-coated magnetic beads (Dynabeads M-280 
Streptavidin) were purchased from Life Technologies (Karlsruhe, Germany). Recombinant 
human activated protein C (APC) was purchased from Eli Lilly (Giessen, Germany). 
Recombinant human activated FXIII A subunit (FXIIIAa) was purchased from Zedira 
(Darmstadt, Germany). The randomized ssDNA libraries IHT1 (5'- AAG CAG TGG TAA GTA 
GGT TGA - N40 (25% each A/G/C/T) - TCT CTT CGA GCA ATC CAC AC -3’) and IHT2N (5'- GAT TGT 
TAC TGT CAC GAG GAT- N40 (40% G, 20% each A/C/T) - ATA GCA CAT TAG TTC AGA TAC -3’) were 
synthesized and PAGE-purified by Microsynth (Balgach, Switzerland). IHT1 and IHT2N-
amplification primers (targeting the shown fixed sequences of the libraries in full length) 
and the below described capture molecules were synthesized and HPLC-purified by 
Eurogentec (Seraing, Belgium). The used BM chemiluminescence substrate was 
purchased from Roche (Mannheim, Germany).   
3.3.2. Prediction of DNA hybridization profiles and design of capture-
molecules 
The fraction of DNA duplexes (capture molecule - target ssDNA) over temperature 
(‘melting curves’) of a given sequence under given buffer conditions (concentration of 
capture-molecules, monovalent ions, and Mg2+ ions) was assessed using the ‘DNA 
thermodynamics & hybridization’ tool available on the ‘biophysics’ sub-domain of 
idtdna.com (http://biophysics.idtdna.com). This sub-domain runs stable and tested 
software to be included into the IDT SciTools collection 87. Details on applied formulas and 
calculations can be found at http://biophysics.idtdna.com/HelpMelt.html. The applied 
software returned the predicted fractions of duplex (0 to 1) over an integer temperature 
range of 0 to 100°C. No absolute accordance to real-world conditions was expected. 
However, obtained values were used as a basis for the design of the IHT1- and IHT2N-
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capture-molecules and to assess the chosen concentration of monovalent cations within 
the used washing buffer. Based on the returned data (melting profiles), the following 
sequences were chosen for the capture-molecules: 
 
IHT1-capture-molecule:  5’-Biotin-GTG TGG ATT GC-3’ 
IHT2N-capture-molecule:  5’-Biotin-GTA TCT GAA CTA AT-3’ 
 
Temperatures at which 5%, 50%, or 95% of duplexes (capture molecule - target ssDNA) 
were predicted to be denatured were assessed from the returned data sets. For the IHT1-
capture-molecule, the corresponding values for each step of CaR are shown in Scheme 
3.1 of the main manuscript. Figure S 3.1 shows the returned melting profiles at different 
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Figure S 3.1. (A) IHT2N-related melting curves (capture molecule - target ssDNA) as predicted by 
the ‘DNA thermodynamics & hybridization’ tool. Underlying buffer conditions: Capturing step: 
circles; Washing step: boxes; Release: triangles. (B) Details on buffer conditions and melting 
temperatures at which 5% [Tm(05)], 50% [Tm(50)], or 95% [Tm(95)] of captured ssDNA molecules 
are predicted to be released from the capture molecules.  
 
3.3.3. Binding of capture-molecules to streptavidin-coated magnetic 
beads (SMB) 
5’-biotinylated capture-molecules were bound to SMB as follows. Dynabeads M-280 
Streptavidin (SMB) were washed 3x using B&W buffer (5 mM Tris-HCl, 1 M NaCl, 0.5 mM 
EDTA, pH 7.5) followed by incubation with B&W containing 1 µM of capture molecules 
(200 µl for each mg of SMB > 200 pmole of capture molecules / mg of SMB). The mixture 
was incubated at RT for 30 min under vigorous shaking to prevent beads from settling. 
After incubation, SMBs were washed 3x using B&W- (without EDTA). For storage, loaded 
SMB were suspended in 1 × PBS, 1 mg/ml BSA, 0.2 mg/ml NaN3, pH 7.4 and stored at 4°C 
until used. Before use, the needed amount of stored (loaded) SMB was washed 3x using 
B&W-.  
3.3.4. Assessment of binding and adverse release of capture 
molecules to/ from SMB using fluorescence measurements 
In order to assess the amount of capture-molecules bound to or release from the SMB, 3’-
FAM-labelled IHT1-capture-molecules (5’-biotinylated) were applied. After adding to 
B&W at 1 µM concentration, each 200 µl of this solution were incubated with 1 mg of 
SMB (washed 3x using B&W) for 30 min under vigorous shaking. Subsequently, beads 
were removed by magnetic force and the amount of FAM-labelled molecules remaining in 
the supernatant was determined by fluorescence measurements using black 96-well 
microtiter plates and a Synergy 2 microplate reader (Biotek, Bad Friedrichshall, Germany) 
and a λex 485 / λem 528 nm filter set.  
To assess the temperature-dependent detachment of capture molecules from the SMBs, 
3’-FAM-labelled IHT1-capture-molecules (5’-biotinylated) were bound to the SMB as 
described above. After incubation in ultrapure water (1 mg loaded SMB / 20 µl) at 
different temperatures, the absolute amount of fluorescence in the supernatants was 
measured.  
The FAM-labelled IHT1-capture-molecules could be detected down to sub-nanomolar 
concentrations in TE-buffer (20 mM Tris-HCl, 1 mM EDTA, pH 8.0). Thus, solutions to be 
tested were diluted in TE-buffer and the relative or absolute amounts of capture-
molecules quantified by the standard-curve method.  
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Regarding determination of SMB-binding-capacity, merely 5% of the total fluorescence 
remained within the supernatant when using varying amounts of SMB around 1 mg, 
indicating efficient binding of capture-molecules when using 1 mg of SMB for 
immobilization of 200 pmole of (non-fluorescent) capture-molecules (Figure S 3.2). 




Figure S 3.2. Binding of 3’-fluorescently-labelled capture molecules to SMB introduced in different 
amounts. Values represent the relative amount of fluorescence that remained in solution after 
incubation.     
3.3.5. Exponential amplification and asymmetric PCR 
Initial exponential amplification of IHT1- or IHT2N-target-molecules was performed in a 
final volume of 100 µl using the following reaction mixtures and cycling conditions: 1 x 
PCR buffer (containing Tris-HCl, pH 8.7, KCl, and (NH4)2SO4), 1.5 mM MgCl2, 200 µM each 
dNTP, 1 µM each forward- and reverse-primer, 1.25 U HotStarTaq Plus DNA polymerase, 
and 20 µl of the sample. Thermal cycling was done using the following profile: 95°C for 3 
min followed by the indicated number of cycles of 95°C for 30 sec, 56°C (IHT1) or 58°C 
(IHT2N) for 30 sec, and 72°C for 30 sec.  
For the production of target single-strands, asymmetric PCR was applied using the 
reaction mixtures and conditions as described for the exponential amplification but 
without reverse primers. Ten µl of a 1 in 10 dilution of previously cycled exponential 
amplification mixtures were used as template. Before introduction to CaR, pooled 
reaction mixtures were spiked with a final concentration of 100 mM NaCl (using a 5 M 
stock solution). 
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3.3.6. Production of asymmetrically amplified IHT1-library for 
evaluation purposes 
Asymmetrically amplified IHT1-library that was applied for evaluation purposes was 
prepared as follows. For initial exponential amplification, 10 µl of a 167 nM solution of 
the original IHT1-ssDNA-library (1012 molecules) were added to the mastermix and 
amplified for 15 cycles. Subsequently, 50 cycles of asymmetric PCR were performed after 
introduction of 10 µl of 1 in 10 diluted exponential amplification products.       
3.3.7. Assessment of quality and purity of ssDNA after asymmetric 
PCR/ CaR during basic assay evaluation   
It should be noted that no special efforts were done to optimize the yield of ssDNA as 
produced by asymmetric PCR during this study which solely focused on the general 
functionality of the CaR procedure. Thus, total yields of isolated ssDNA may increase in 
case of further optimization of the asymmetric PCR procedure. 
Single bands of dsDNA or ssDNA were observed when performing gel analysis of 
asymmetrically amplified IHT1-molecules (Figure S 3.3A, lane 1 and Figure S 3.4, lane 1). 
In order to assess the release of captured ssDNA at different elution temperatures, 500 µl 
of crude pooled asymmetric IHT1-reaction mixtures were added to 1 mg of SMB loaded 
with 200 pmole of IHT1-capture molecules (SMB+). After incubation for 30 min at RT, the 
SMB+ were washed 3x at RT using 1000 µl of 10 mM Tris-HCl, 20 mM NaCl, pH 7.6 and 
finally taken up in 20 µl of ultrapure water pre-heated to designated temperature (RT, 
37°C, 43°C, or 50°C). After 2 min of incubation in a water bath set to corresponding 
temperature, SMB+ were separated by magnetic force and supernatants collected. The 
final elution step was repeated 2x using new batches of water.  
As shown in Figure 3.1A of the main manuscript, the majority of captured ssDNA was 
readily released from the IHT1-capture molecules at elevated temperatures during the 
first elution step. The quality of achieved ssDNA (see Figure 3.1A for total yields) was 
determined by gel analysis (Figure S 3.3A) while yield and purity was assessed by triplicate 
UV-measurements (A260/A280 ratios) using a NanoDrop® ND-1000 UV/Vis-
Spectrophotometer (Thermo Scientific) (Figure S 3.3B).       
 
 




Figure S 3.3. (A) Agarose gel analysis (stained with ethidium bromide) of ssDNA yielded by CaR 
during the first elution at different temperatures. Lane 1: introduced crude asymmetric IHT1-PCR 
mixture. Lanes 2, 4, 6, and 8: 1 in 10 dilutions of ssDNA released from the IHT1-capture molecules 
at RT, 37°C, 43°C and 50°C, respectively. Lanes 3, 5, 7, and 9: corresponding supernatants 
(asymmetric PCR mixtures) after incubation with SMB+. Lane 10: 50 bp dsDNA ladder. (B) 
A260/A280 ratios of obtained ssDNA as determined by UV-measurements. 
In order to provide further evidence for the proposed principle of CaR, underlying 
sequence-specificity was verified by the use of SMB loaded with IHT2N-capture molecules 
during CaR being performed with asymmetrically amplified IHT1-library. Besides SMB 
loaded with IHT1-capture molecules, also non-loaded beads that were passed through all 
incubation/ washing steps as described in ‘Binding of capture-molecules to streptavidin-
coated magnetic beads (SMB)’ (but in the absence of capture molecules), were run in 
parallel as controls. Again, 500 µl of crude pooled asymmetric PCR mixtures and 1 mg of 
SMB were used during each reaction. 
As shown in Figure S 3.4, only the use of IHT1-capture molecules yielded detectable 
amounts of IHT1-ssDNA as determined by gel analysis (see Figure 3.1B for obtained yield). 
The corresponding A260/A280 ratio was found to be 1.97 for the first elution. 
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Figure S 3.4. Yield and quality of ssDNA isolated from IHT1 asymmetric amplification by CaR using 
non-loaded SMB or SMB loaded with specific (IHT1) or non-specific (IHT2N) capture molecules. 
Lane 1: introduced crude asymmetric IHT1-PCR mixture. Lanes 3, 5, and 7: 1 in 10 dilutions of 
ssDNA as obtained by the use of IHT1-capture molecules, IHT2N-capture molecules or non-loaded 
SMBs, respectively. Lanes 2, 4, and 6: corresponding supernatants (asymmetric PCR mixtures) 
after incubation with loaded or non-loaded SMB.  
 
3.3.8. Quantification of streptavidin released from the SMB 
Non-loaded SMB that were passed through all incubation / washing steps as described in 
‘Binding of capture-molecules to streptavidin-coated magnetic beads (SMB’) (but in the 
absence of capture molecules), were applied to assess the potential adverse 
contamination with streptavidin at different incubation temperatures. Concentrations of 
streptavidin were measured by an immunoassay as follows. Primarily, Maxisorp 
microtiter modules were coated with 10 µg/ml BSA-Biotin (100 µl/well) in coating buffer 
(30 mM Na2CO3, 200 mM NaHCO3 [pH 9.0]) overnight at 4°C followed by 3 times rinsing 
with 300 µl of washing buffer (1 x PBS [pH 7.4], 3 mM MgCl2, 0.05 % Tween 20; general 
washing procedure using an automated plate washer [ELx50, Biotek, Bad Friedrichshall, 
Germany]). Remaining binding sites were blocked by incubation with blocking buffer 
(1xPBS [pH 7.4], 2 mg/ml BSA, 0.05 % Tween 20) for 2h at RT. After incubation for 2h at 
RT, remains were aspirated and sealed modules stored at 4°C until used. To run the assay, 
standards or samples were diluted in washing buffer containing 1 mg/ml BSA (WB+) and 
100 µl of the dilutions were added to the wells and incubated for 1h at RT. After washing, 
100 µl of rabbit whole antiserum against streptavidin (diluted 1:2000 in WB+) were added 
to the wells and also incubated for 1h at RT. Subsequently, wells were washed and 100 µl 
of HRP-labelled goat anti-rabbit antibodies (diluted 1:2000 in WB+, yielding a final 
concentration of 0.125 µg/ml) added and incubated for another hour at RT. Finally, after 
washing, bound HRP was detected using BM chemiluminescence substrate (100 µl well) 
and a Synergy 2 microplate reader (Biotek, Bad Friedrichshall, Germany). Applied 
streptavidin standard curves were prepared by half-logarithmic dilution series and 
showed a linear range from 530 down to 1.7 pM (31.6 down to 0.1 ng/ml). Original 
samples were diluted in WB+ to match the covered range and the absolute content of 
streptavidin calculated. The corresponding results are shown in Figure 3.1C.  
3.3.9. CE-SELEX against APC and FXIIIAa   
CE-based separations were performed using a PA800 capillary electrophoresis system 
(Beckman Coulter, Krefeld, Germany) and 32 Karat software. A 60 cm long (50 cm to the 
detection window) uncoated fused silica capillary with an inner diameter of 50 µm 
(Beckman Coulter) was conditioned before the first use and rinsed between runs with an 
pressure of 50 psi (for 5 min each) with 100 mM HCl, 100 mM NaOH, destilled water, and 
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selection / separation buffer (25 mM Tris-HCl, 30 mM NaCl, 1 mM KCl, 1 mM CaCl2 and 1 
mM MgCl2, pH 8.3). Applied ssDNA-libraries (IHT1 or IHT2N) were added to 20 µl of 
selection buffer in a final concentration of 25 µM (500 pmole) for the first selection cycle 
and heated to 85°C for 5 min followed by snap cooling on ice. Subsequently, the target 
protein (either APC or FXIIIAa) was added and the mixture was incubated at RT for 30 min 
before hydrodynamic injection into the capillary (using 4 psi pressure for 5 second, 
thereby introducing ~ 40 nL of the sample into the capillary). Separation of protein from 
non-binding ssDNA-molecules took place under electroosmotic flow at a voltage of 25 kV. 
As determined during previous experiments, the collection window was set during the 
first 20 min of separation. Samples were collected into tubes containing 150 µl of 
separation buffer. Library molecules that remained in the capillary were flushed out by 
reverse rinsing. A total of 120 µl of the collected molecules (6 x 20µl) were exponentially 
amplified for 30 (IHT1) or 35 (IHT2N) cycles. Subsequently performed asymmetric PCR 
was routinely conducted for 50 cycles. In case of formation of unwanted by-products (as 
determined by gel-analysis), however, cycle numbers of asymmetric PCR were reduced to 
30 - 45 in order to retain amplification specificity. Subsequently, single reactions were 
pooled and a total of 500 µl introduced to CaR for isolation of ssDNA. At this, captured 
ssDNA was eluted at 43°C. A constant amount of enriched library (0.5 µM; 20 pmole) was 
used during the following selection cycles. In contrast, the concentration of the target 
enzymes was gradually reduced from 1 µM during the first selection cycle to low nM-
concentrations during the sixth (last) cycle.  
 
3.3.10. Yield and purity of ssDNA as produced by asymmetric PCR/ CaR 
during SELEX       
The following Tables S 3.1 - S 3.3 show the yield and purity of ssDNA obtained from 
asymmetric PCR/ CaR during the process of SELEX as determined by UV-measurements.    
 
Table S 3.1. Yield and purity of ssDNA after each cycle of IHT1-based APC-SELEX. 












A260 1.48 1.05 1.022 0.645 1.121 0.811 
A280 0.781 0.576 0.542 0.335 0.606 0.426 
A260/A280 1.9 1.83 1.89 1.92 1.85 1.90 
Conc. [µM] 1.95 1.39 1.34 0.85 1.48 1.07 
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A260 0.715 1.46 1.06 1.134 1.038 1.185 
A280 0.408 0.74 0.535 0.577 0.522 0.631 
A260/A280 1.75 1.96 1.98 1.96 1.99 1.88 
Conc. [µM] 0.93 1.90 1.38 1.48 1.35 1.54 
 













A260 0.469 1.048 1.353 1.235 1.130 1.719 
A280 0.245 0.530 0.715 0.668 0.601 0.885 
A260/A280 1.91 1.98 1.89 1.85 1.88 1.94 
Conc. [µM] 0.62 1.38 1.78 1.63 1.49 2.26 
 
3.3.11. Filter retention assay  
The affinity of the single-stranded random pools, enriched libraries, and obtained single 
aptamer molecules was assessed by filter retention assay. Molecules (10 pmole) were 
radioactively 5′-phosphorylated using 20 U of T4 Polynucleotide Kinase (New England 
Biolabs, USA) in 70 mM Tris–HCl buffer [pH 7.6] containing 10 mM MgCl2, 5 mM 
dithiothreitol, and 300 μM [γ-32P]ATP (PerkinElmer, USA) and then purified using G-25 
microspin columns (GE Healthcare, Munich, Germany). The integrity of the enriched 
libraries was qualitatively determined using 12% denaturing polyacrylamide gel 
electrophoresis. 
To determine the dissociation constants, serially diluted APC or FXIIIAa (0-1 µM) were 
incubated with 0.5 nM 32P-labeled ssDNA for 30 min at 37°C in PBS [pH 7.4] containing 1 
mg/ml BSA, 10 µM tRNA, 1 mM CaCl2 and 50 µM MgCl2. After incubation, the reactions 
were passed through pre-equilibrated 0.45 µm nitrocellulose membranes followed by 
three washings using 150 μl of PBS [pH 7.4] containing 1 mM CaCl2 and 50 µM MgCl2 and 
then dried out. The retained radioactivity was quantified using a FUJIFILM FLA-3000 
PhosphorImager equipped with AIDA Imagequant software (Fujifilm, Düsseldorf, 
Germany). Data were fitted by 4-parameter logistic curve fit presuming a 1:1 binding 
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stoichiometry of ssDNA:target protein. Kd values were determined from at least two 
independent experiments.  
 
3.3.12. Cloning and sequencing 
The aptamer pool from the SELEX cycle that showed the highest apparent binding affinity 
was cloned into pGEM®-T vectors (Promega, Mannheim, Germany). For the IHT1- and 
IHT2N-based selections against APC, 19 and 32 colonies were sequenced, respectively. 
For the IHT1-FXIIIAa-selection, 32 colonies were sequenced. Sequencing was done using 
M13 primers and an ABI 3130xl Genetic Analyzer (Applied Biosystems, Darmstadt, 
Germany).  
 
3.3.13. Production of identified individual aptamers by asymmetric 
PCR/ CaR and determination of binding affinity 
Identified single aptamers were produced from PCR-products using asymmetric/ CaR. 
Aptamers were radioactively labeled and tested for binding affinity as described above. 
The capture-efficiency and quality of the yielded ssDNA is demonstrated in Figure S 3.5. 
The results of the filter retention analysis are shown in Figure S 3.6.  
As can be seen in Figure S 3.5, probably due their individual tertiary structures, single 
monoclonal ssDNA aptamers did not clearly separate from the corresponding double-
stranded PCR products during electrophoresis. This was especially true for the FXIIIAa-
aptamers and the aptamers #2 and #3 of the IHT2N-based selection against APC. In cases 
were distinct bands of ssDNA could be assessed, virtually complete capturing of ssDNA 
from the asymmetric PCR mixtures could be observed.           
 




Figure S 3.5.  Agarose gel analysis (stained with ethidium bromide) of asymmetric PCR mixtures, 
obtained ssDNA (1:10 diluted) and supernatants after removal of loaded SMB (from left to right 
within each group) after introduction of identified single aptamer-clones to asymmetric PCR/ CaR. 
A, B: selection against APC using the IHT1 (A) and IHT2N library (B) respectively. C, selection 
against FXIIIAa using the IHT1 ssDNA library. A 50bp dsDNA-ladder was used in each gel. 




Figure S 3.6. Filter retention analysis of individual aptamers. (A) IHT1-based APC-SELEX. (B) IHT2N-
based APC-SELEX. (C) IHT2N-based FXIIIAa-SELEX. Shown KD-values were determined by 4-
parameter logistic curve fit; n.d., not determined; N/A, no binding observed up to 1 µM.  
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3.3.14. In silico folding predictions 
The mfold web sever as available at: http://mfold.rna.albany.edu/?q=mfold/dna-folding-
form was used at default settings to predict the folding patterns of the identified single 
aptamers 91. Predicted foldings of the 4 efficiently binding APC-aptamers are shown in Fig. 
S7. As expected, the 3’-ends of the single sequences appear to be accessible to the 
corresponding capture molecules. The same was found for the FXIIIAa-binding aptamers 
(data not shown). However, since these predictions are limited to Watson-Crick base 
pairing in two-dimensional space, their validity is limited. 
 
Figure S 3.7. Folding patterns of the identified APC-binding aptamers as determined by mfold. 
 
3.3.15. Determination of the reusability of loaded SMB 
Clone #1 identified during IHT1-based selection against APC was used to assess the 
reusability of SMB loaded with (IHT1) capture molecules (SMB+). After release of 
captured ssDNA by 3 consecutive incubations with a fresh batches of water, SMB+ were 
washed and again introduced to the CaR-procedure. In total, 4 cycles of capture and 
release were performed. As shown in Figure S 3.7, virtually complete capturing of ssDNA 
from the asymmetric PCR mixtures could be observed. As shown in Table S 3.4, 
comparable yields and purities were found.     





Figure S 3.8. Agarose gel analysis (stained with ethidium bromide) of obtained ssDNA by 
consecutive usage of SMB+ during CaR. Lanes 1, 4, 8, and 11: introduced crude asymmetric PCR 
mixture; lanes 2, 5, 9, 12: 1 in 10 dilution of yielded ssDNA when using SMB+ for the first, second, 
third and fourth time, respectively; lanes 3, 6, 10 and 13: supernatants after incubation of 
asymmetric PCR mixture with the SMB+ for the first, second, third and fourth time, respectively; 
lane 7: 50 bp dsDNA ladder. 
 
Table S 3.4. Yield and purity of ssDNA obtained after consecutive use of SMB+. 
 1st use 2nd use 3rd use 4th use 
A260 0.432 0.513 0.524 0.508 
A280 0.214 0.246 0.272 0.261 
A260/A280 2.02 2.08 1.93 1.95 
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Protease exosites act as key regulator elements of protease function. Here we 
investigated, if the functions of activated protein C (APC) can be modulated by exosite 
binding aptamers. APC is a multifunctional serine protease that controls blood 
coagulation and exhibits anti-inflammatory and cytoprotective functions. We showed that 
APC-aptamers binding to the basic exosite selectively inhibit the anticoagulant functions 
of APC and can be used to enhance or inhibit the inactivation of APC by endogenous 
inhibitors resulting in a drastically reduced or enhanced catalytic life of APC. While 
enhancing the catalytic life of APC offers an interesting approach in the treatment of 
septicemia and in the prevention of tissue damage after arterial infarction, selective 
inhibition of the anticoagulant functions of APC is of particular interest in the prevention 
of APC-induced bleeding such as in trauma-induced coagulopathy and as supportive 
treatment approach in hemophilic patients. 
4.2. Main manuscript 
Activated protein C (APC) is a multifunctional serine protease that controls blood 
coagulation by down-regulation of thrombin formation 8. APC is generated from its 
inactive precursor protein C (PC) on the surface of endothelial cells in a thrombin-
dependent manner. This process is augmented, if PC is bound to the endothelial cell 
protein C receptor (EPCR). APC that is released into the flowing blood acts as an 
anticoagulant by proteolytic cleavage of the activated cofactors V (Va) and VIII (VIIIa), 
while APC that remains bound to EPCR expresses cytoprotective functions involving 
cleavage of protease receptors-1 and -3 (PAR-1/PAR-3) 92–94.  
Dysfunctions of the APC-pathway either inherited or acquired are involved in the 
pathogenesis of various thrombo-inflammatory diseases. Patients with mild to moderate 
inherited PC-deficiency are at an increased risk for venous thromboembolism, while 
severe PC-deficiency is associated with a high risk to develop purpura fulminans, a severe 
thrombo-inflammatory disorder, affecting the microvasculature of the skin and vital 
organs 95–97. Acquired APC dysfunction is observed in patients with septicemia where it is 
involved in the development of microvascular thrombosis leading to severe organ 
dysfunction and organ failure 98,99. Overwhelming APC formation has been described in 
trauma patients and seems to be a critical factor in the development of trauma-induced 
coagulopathy 100,101. 
Its involvement in the pathogenesis of various thrombo-inflammatory disorders makes 
APC and the PC-pathway to attractive candidates for therapeutic interventions. A plasma 
purified PC concentrate is successfully used in the treatment of severe PC-deficiency and 
of meningococcal septicemia 102,103. A recombinant version of APC, drotrecogin alfa, has 
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been shown to decrease 28-day mortality in severe sepsis but was withdrawn from the 
market because the positive outcomes could not be confirmed in follow-up studies 24,25. A 
major complication of APC treatment was the development of bleeding. Since the 
therapeutic efficacy of APC in the treatment of severe sepsis is mainly based on its 
cytoprotective properties, mutants were generated showing diminished anticoagulant 
activities but preserved cytoprotective functions 104,105. The catalytic-life of APC in whole 
blood is approximately 20 min and regulated by two natural inhibitor proteins, namely 
alpha1-antitrypsin and protein C inhibitor (PCI) 106,107. Substitution at Leu194 generates an 
APC mutant showing a 4-6-fold prolonged half-life 108. Although these variants suggest 
therapeutic opportunities, their production is cost intensive and they compete with wild-
type endogenous APC for receptor signaling, leading to the need of high dosages.  
Modulation of the APC activity by small molecules or other compounds could be an 
attractive alternative to genetically engineered APC variants. Besides the active center, 
the basic and acidic exosites of APC are interesting target regions for such an approach. In 
this study we used the aptamer technology to study if the APC activity can be selectively 
inhibited and/or the catalytic life of APC modulated. To increase the probability to select 
distinct APC binding sequences we used several selection strategies. In addition to 
previously applied conventional SELEX procedures, capillary electrophoresis (CE)-based 
SELEX (CE-SELEX) was used and different randomized ssDNA-libraries were applied, 
including a G-enriched library to increase the likelihood of selecting G-quadruplex 
containing aptamers. Using these approaches, a variety of aptamers has been selected 
showing binding affinities to APC ranging from 0.2 to 20 nM (Table S 4.1) and no 
significant binding to the structurally related serine proteases thrombin and activated 
factor VII as well as to the APC precursor PC (Table S 4.2). Remarkably, a previously 
described consensus sequence (5‘-TATCMCGNATGGGS-3‘), that was identified during two 
independent runs of conventional SELEX, also dominated CE-SELEX (Figure 4.1A). As 
assessed by next generation sequencing (NGS) (Figure S 4.1), each CE-based selection was 
dominated by one individual aptamer that contained this consensus sequence. The 
maximum enrichment comprised more than 80% of sequences independent of the type 
of library used (Figure S 4.1). Such an enrichment during CE-SELEX appears to be 
unparalleled and indicates that the degree of heterogeneity achieved during aptamer 
selection is mainly influenced by the target molecule whereas the applied selection 
strategy is of minor influence. However, a structurally different APC aptamer (NB3) could 
be selected from the G-enriched library. Thioflavin T staining of original and selected 
truncated aptamer variants (Figure S 4.2) confirmed the presence of a G-quadruplex 
structure within the NB3-aptamer (Figure 4.1B / Figure S 4.3). Furthermore, as assessed 
by in silico analysis, this putative G4 motif seems not to be involved in intramolecular 
Watson-Crick base pairing (Figure 4.1A), indicating that aptamer NB3 might indeed be 
dominated by a G4 structure. This assumption is further supported by the relatively high 
free energy value (delta G) of the mfold-based NB3 secondary structure that indicates a 
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relatively low stability and therefore suggests the presence of an alternate, more stable 
pattern within the predicted loop-section of the NB3 aptamer.   
To localize the binding region of the newly selected aptamers, crossblocking experiments 
using previously characterized APC binders have been performed. The NB-aptamers 
compete with the APC-aptamer HS02-52G and unfractionated heparin for binding to the 
basic exosite as assessed by crossblocking experiments (Figure 4.1C, Figure S 4.4).  
 
Figure 4.1. Structure and binding characteristics of APC aptamers. (A) In-silico-prediction of 
secondary structures and key characteristics extracted from m-fold web server on 09/17/2015. 
The consensus sequence is shown in highlighted format, G-quadruplex forming nucleotides have 
been defined by a surrounding quadrangle. Dissociation constants (Kd) measured by filter 
retention assay are shown in nM. (B) G-quadruplex detection assay. SYBRGreen or ThT (1 µM) 
were incubated with aptamers at a final concentration of 1 µM in microtiter plates followed by 
fluorescence measurement in λex/ λem of 425/500 nm and 497/520 nm for ThT and SYBRGreen, 
respectively. A G4 forming sequence, 45Ag, was used as positive control while the sequence 
45noG4 lacking the ability to form G4 structures was used as negative control. Error bars 
correspond to standard deviation of three measurements. (C) Unlabeled crossblocking 
experiments. NB-aptamers at the indicated concentrations were incubated with rAPC (final 
concentration: 180 pM). Subsequently the reaction mixture was transferred to wells of a 
microtiter module coated with HS02-52G aptamers. The amount of APC bound to HS02-52G was 
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measured through hydrolysis rates of an APC-specific fluorogenic peptide substrate. Results are 
shown as means of duplicates. 
 
Protein-binding aptamers have been reported to affect molecular interactions distantly 
from their binding site 109. Hence, we studied if the APC aptamers interfere with the 
catalytic center of APC by studying the hydrolysis rates of two distinct peptide substrates. 
All APC-aptamers led to a partial decrease in conversion rates of the sensitive fluorogenic 
substrate Pyr-Pro-Arg-AMC, albeit on different levels (Figure 4.2A). With a maximum 
reduction of 25% NB2- and NB3-aptamers showed a weaker inhibitory effect than NB1 
and HS02-52G. Similar results were obtained, when the fluorogenic substrate was 
replaced by a chromogenic substrate (p-Glu-Pro-Arg-MNA) or if truncated variants of the 
aptamers were tested (Figure S 4.5). These results strongly suggest that the inhibitory 
effect of the aptamers on substrate conversion is based on allosteric rather than steric 
effects and that this effect depends on the individual sequence of the aptamers. 
As expected from the proposed binding site, all APC aptamers showed a dose-dependent 
inhibition of APC-induced FVa cleavage as tested using a prothrombinase assay (Figure 
4.2B). Full inhibition was achieved with NB1, NB2, and HS02-52G, whereas full-length NB3 
only partially inhibited the APC induced proteolysis of FVa. The lower effect of NB3 is also 
reflected by the corresponding IC50 values (Table S 4.3). In this experimental approach, 
the impact of aptamers on the activity of exogenously added APC in a purified system was 
tested. However, these results not necessarily reflect the in-vivo situation where APC is 
continuously generated through the thrombin-TM complex and where aptamers might 
interact with a variety of plasma components and blood cells. To study the influence of 
the APC aptamers on endogenously generated APC within the  plasma  matrix, we 
initiated thrombin formation in plasma in the presence of recombinant thrombomodulin. 
The results confirmed that all APC aptamers inhibit the anticoagulant activities of APC 
albeit on a different level. In contrast to the results obtained using the prothrombinase 
assay, NB3 was found to be a more potent APC inhibitor than NB1 and NB2. Among all 
APC aptamers tested a truncated version of NB3 (NB3-49) and HS02-52G were found to 
be the most efficient ones (Figure 4.2C). NB3-49 was found to be an effective APC 
inhibitor but on a lower level compared to HS02-52G when replacing plasma by whole 
blood (Figure 4.2D).  




Figure 4.2. Functional properties of APC aptamers. (A) Influence of APC aptamers on peptide 
substrate conversion. Increasing concentrations of APC aptamers were incubated with rAPC at a 
final concentration of 180 pM and hydrolysis rates of a fluorogenic peptide substrate (Pyr-Pro-
Arg-AMC) were measured. Substrate conversion measured w/o aptamers was set as 100%. (B) 
Influence of APC aptamers on APC catalyzed FVa-proteolysis. Purified FVa (150 pM) was incubated 
with rAPC (4.5 pM) in the presence of increasing concentrations of APC-aptamers for 30 min. 
After addition of FXa (1.3 pM) and prothrombin (25 nM) the amount of thrombin formed was 
measured through hydrolysis rates of a fluorogenic thrombin substrate. (C) Influence of APC 
aptamers on the anticoagulant activity of endogenously generated APC in human plasma. Pooled 
normal human plasma was spiked with rabbit thrombomodulin (2 U/ml) and increasing 
concentrations of APC aptamers. Subsequently, thrombin formation was initiated by addition of 
recombinant tissue factor (5 pM) and the time-dependent amount of thrombin generated 
monitored through the endogenous thrombin potential (ETP). (D) APC inhibiting activities of APC 
aptamers in whole blood. Contact phase activator (50 µl) was added to 100 µl of citrated whole 
blood containing different concentration of each aptamer. Time to clot formation was detected 
subsequent to addition of CaCl2 (25 mM). 
 
A higher stability of the NB3 aptamers containing a stable G4-structure might explain the 
higher efficacy of this aptamer when compared to the other NB-aptamers. Owing to its 
substantial Watson-Crick-based stem region, such a stability effect may also determine 
the high inhibiting capacity of HS02-52G.  
However, besides blocking the binding sites for the procoagulant substrates FVa and 
FVIIIa (Figures S 4.6 – 4.7), the APC activity can also be inhibited by modulating 
endogenous control mechanisms. Similar to unfractionated heparin, the HS02-52G 
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aptamer accelerates the rate of APC inactivation by PCI following a template mechanisms 
13. From genetically engineered APC variants it is known that replacement of amino acids 
at position 194 and 254 generates an APC variant resistant to endogenous inhibition 
resulting in a prolonged half-life 108. Since these sites are located within or nearby the 
basic exosite of APC, we studied if the APC NB-aptamers 1-3 influence the inactivation 
rates of APC similar to HS02-52G. Studying plasma half-life times in the presence of 
saturating concentrations of the APC aptamers, the aptamers NB1 and NB2 similar as 
HS02 increased APC inactivation rates but on a lower level (Figure 4.3A). The reduced 
half-lifes correlated well with the increased formation of APC-PCI complexes as tested by 
a sandwich ELISA. Most interestingly, however, the G-quadruplex-based NB3 aptamer 
varients, protected APC from APC/PCI-complex formation (Figure 4.3B).  
 
Figure 4.3. Influence of APC aptamers on inhibition of APC by endogenous inhibitors. (A) 
Recombinant APC (final concentration of 1.9 nM) was spiked to PC-deficient plasma in the 
presence of 100 nM NB aptamers followed by sub-sampling and capturing of APC using sheep 
anti-human PC antibody primed plates. Residual activity of APC was measured through 
fluorogenic peptide substrate conversion. (B) Subsequently, a HRP-conjugated goat anti-human 
PCI antibody was added to the wells and APC-PCI complex formation was monitord using BM 
chemiluminescence substrate. The luminescence intensity corresponds to the time point of 120 min 
incubation of HS02-52G aptamer was considered as 100% value. NB1-83, solid circles; NB2-81, 
solid triangles; NB3-82, solid squares; HS02-52G (positive control), open squares; AD02-52, open 
diamonds. Results are shown as means of duplicates. (C) Categorization of APC aptamers based on 
their impact on functions of APC. 
 
Overall, as outlined in figure 4.3C the aptamers can be categorized in APC anticoagulant 
activity inhibiting aptamers with and without heparin-like activities and a third class of 
APC anticoagulant inhibitors inducing resistance to endogenous APC inhibitors. Since the 
acidic exosite of APC is not involved in aptamer binding the allosteric aptamers show no 
effect on the cytoprotective functions of APC 13. These features qualify NB3 as a novel 
candidate molecule for the development of a specific and potent APC inhibitor as 
envisaged for the adjuvant treatment of patients with hemophilia 110–112. Furthermore, 
rapid and selective down-regulation of the anticoagulant activity of APC seems to be 
especially interesting in trauma-induced coagulopathy (TIC) patients where a reversible 
and short acting APC inhibitor is required and where active-site acting inhibitors bear the 
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risk to induce an adverse thrombo-inflammatory reaction. Moreover this study shows 
that aptamers can be used to study and dissect different functional epitopes within a 
protease exosite not only adding new insights into the architecture and organization of 
the basic exosite of APC but also showing that aptamers are useful for epitope binning 
similar to monoclonal antibodies. 
4.3. Supplementary information 
4.3.1. Chemicals and materials  
All basic chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany). The 
randomized single-stranded (ss) DNA libraries IHT1 (5'- AAG CAG TGG TAA GTA GGT TGA - 
N40 (25% each A/G/C/T) - TCT CTT CGA GCA ATC CAC AC -3’), IHT2N (5'- GAT TGT TAC TGT 
CAC GAG GAT- N40 (40% G, 20% each A/C/T) - ATA GCA CAT TAG TTC AGA TAC -3’), 
individual aptamers HS02-52G and 3’-biotinylated HS02-52G (5’-GCC TCC TAA CTG AGC 
TGT ACT CGA CTT ATC CCG GAT GGG GCT CTT AGG AGG C-3’), NB1, NB2, and NB3 (see 
Table 1 for sequences), as well as the control oligonucleotides AD02-52 (5’-GCC TCC TAA 
GAG CCC CAT CCG GGA TAA GTC GAG TAC AGC TCA GTT AGG AGG C-3’), 45Ag (5’-GGG 
TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG TTA GGG -3’) and 45noG4 (5’- 
CAT ACA TAC ATT TCA CAA TTC ACA TTA CAT TCA CAA TCC ATT CAT-3’) were synthesized 
and PAGE-purified by Microsynth (Balgach, Switzerland). IHT1 and IHT2N-amplification 
primers and 5’-biotinylated capture molecules for the IHT1 library (5’- Biotin-GTG TGG 
ATT GC-3’) and the IHT2N library (5’- Biotin-GTA TCT GAA CTA AT-3’) were synthesized 
and HPLC-purified by Eurogentec (Seraing, Belgium).  
The composition of the PBS buffer (1x, pH 7.4) was as follows: 137 mM NaCl, 2.7 mM KCl, 
9.6 mM Na2HPO4, and 1.5 mM KH2PO4. The used D-PBS-buffer (containing 0.9 mM CaCl2 
and 0.5 mM MgCl2 in the 1x concentrated solution) was purchased as a 10x concentrate 
at a pH of 5.3 from Sigma (cat. no.: D1283). The pH was adjusted to 7.4 during 
preparation of the 1x concentrated buffer.. Recombinant human activated protein C 
(rAPC, Xigris®) was purchased from Eli Lilly (Windlesham, Surrey, UK), recombinant 
human Factor VIIa (NovoSeven®) was obtained from Novo Nordisk (Bagsværd, Denmark). 
Argatroban was obtained from Mitsubishi Pharma (Düsseldorf, Germany). Human FVIII 
was purchased from CSL Behring (Marburg, Germany). Plasma-derived human Protein C 
(Ceprotin®) was from Baxter (Unterschleißheim, Germany). Unfractionated heparin (UFH) 
was purchased from Ratiopharm (Ulm, Germany). Human alpha-thrombin, activated 
human FIX and human FX was from Haematologic Technologies, Inc. (Essex Junction, USA) 
and was purchased from Cellsystem (Troisdorf, Germany). The aPTT reagent Actin FS was 
purchased from Siemens Healthcare Diagnostics. Phospholipids was obtained from Rossix 
(Mölndal, Sweden). G-25 columns were purchased from GE Health Life Sciences (Freiburg, 
Germany). T4 Polynucleotide Kinase (PNK) was obtained from New England Biolabs 
(Frankfurt, Germany) and [γ-32P] ATP was purchased from PerkinElmer (Rodgau, 
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Germany). The fluorogenic APC peptide substrate PCa 5791 (Pyr-Pro-Arg-AMC) was 
purchased from Loxo (Dossenheim, Germany) and Fluorogenic FXa substrate, I-1100 (Boc-
Ile-Glu-Gly-Arg-AMC) was obtained from Bachem (Weil am Rhein, Germany). The 
chromogenic APC substrate p-Glu-Pro-Arg-MNA was part of the Berichrom Protein C Kit 
(Siemens Healthcare, Marburg, Germany). Reagents for thrombin generation (5 pM TF-
reagent [PPP-reagent], thrombin calibrator, FluCa buffer and the fluorogenic thrombin 
substrate Z-Gly-Gly-Arg-AMC) were purchased from Stago (Düsseldorf, Germany). Rabbit 
thrombomodulin was purchased from Sekisui (Pfungstadt, Germany). Protein C-deficient 
plasma was purchased from Affinity Biologicals (Ontario, Canada).  
 
4.3.2. Capillary electrophoresis-(CE)-SELEX 
All CE separations were performed using the ProteomeLab PA 800 (Beckman Coulter, Inc., 
Fullerton, CA, USA) as previously described 47,113. In brief, 2 independent selections each 
comprising 6 cycles of CE-SELEX against rAPC were performed using the ssDNA-libraries 
IHT1 or IHT2N. The concentration of rAPC within the equilibrium mixture with (selected) 
ssDNA was reduced with each selection cycle to increase stringency. Generation of ssDNA 
for subsequent selection cycles was isolated from asymmetric PCR mixtures by Capture 
and Release (CaR) using the IHT1 or IHT2N capture molecules as previously described 47.      
 
4.3.3. Next generation sequencing and data analysis 
NGS was performed using the Illumina sequencing by synthesis technology on a HiSeq 
1500 instrument. For adapter ligation with some adaptations, the TruSeq DNA PCR-Free 
(LT) sample preparation kit (Ref.15037063, Illumina) was used. A detailed description of 
the sample preparation protocol has recently been published 114. Data processing of the 
raw sequencing data was done by AptaIT (Munich, Germany) using the COMPAS software. 
 
4.3.4. In silico secondary structure predictions 
The ‘DNA folding form’ on the mfold web sever available at 
http://mfold.rna.albany.edu/?q=mfold 91 was used at default settings to predict the 
Watson-Crick-based intramolecular folding patterns of the identified single aptamer 
sequences. The web-based QGRS mapper software available at 
http://bioinformatics.ramapo.edu/QGRS/analyze.php 115 was used at default settings to 
assess the presence of putative G4-forming sequences (G4 motifs) within the aptamers.   
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4.3.5. Detection of G-quadruplex formation by Thioflavin T-staining  
In general, aptamers and G4-positive (45Ag) or negative controls (45noG4) were heated 
to 90°C followed by cooling to RT in G4-buffer (50 mM Tris-HCl, pH 7.5 containing 50 mM 
KCl) and preserved on ice until analyzed. 
For PAGE-analysis, 30 pmol of aptamers and controls were mixed with 40% sucrose 
solution and loaded on native 20% polyacrylamide gels supplemented with 50 mM KCl. 
Electrophoresis was performed at 4°C for 4 hours at 80 volts in running buffer (Tris 
Borate, pH 8.3; 89 mM Tris, 89 mM boric acid, and 20 mM KCl) using a MINI Protean Gel 
System (Bio-Rad, Munich, Germany). Gels were subsequently stained with either 
SYBRGreen (1x) or thioflavin T (ThT, 1 µM) in running buffer and bands analyzed using a 
Chemidoc imaging system equipped with image lab 5.0 software (Bio-Rad). 
For analysis in solution, aptamers and controls (1 µM) were stained in G4-buffer at RT 
with either ThT  (1 µM) or SYBRGreen (1x) using black 96-well ½ AreaPlate microplates 
(Perkin Elmer, Rotgau).  Fluorescence (λex = 425 nm / λem = 500 nm for ThT and λex = 497 
nm / λem = 520 nm for SybrGreen) was measured using a 2300 EnSpire Multimode Plate 
Reader (Perkin Elmer, Rodgau, Germany).      
 
4.3.6. Determination of dissociation constants and binding 
competition experiments 
Determination of binding affinities and binding competition experiments were performed 
using filter retention analysis as previously described in detail 113. In brief, aptamers were 
labeled at the 5’end using PNK and [γ-32P] ATP and labeled molecules purified by the use 
of G25 columns. For determination of dissociation constants (Kd), APC, PC, FVIIa or 
human α-thrombin were serially diluted (0-2 µM) in D-PBS buffer, pH 7.4 containing 0.1% 
BSA and 10 µM yeast tRNA (D-PBS+) and 32P-labeled aptamers added (1 nM final 
concentration). During HS02-52G competition experiments, increasing concentrations of 
non-labeled aptamers (0-1 µM) were incubated with APC (20 nM final concentration) for 
10 min followed by addition of 32P-labeled HS02-52G molecules (1 nM final 
concentration). For UFH competition experiments, increasing concentrations of non-
labeled UFH (0-500 µM final concentration) were incubated with APC (20 nM final 
concentration) for 10 min followed by addition of 32P-labeled aptamers (1 nM final 
concentration). In general, reaction mixtures were incubated for 30 min at 37°C and 
subsequently passed through pre-equilibrated 0.45 µm nitrocellulose membranes 
followed by three washes using D-PBS+. The radioactivity remaining on the filter was 
quantified after exposure to a phosphor screen by a FLA 5100 imaging system (Fujifilm 
Life Science, Düsseldorf, Germany).  




4.3.7. OECA-based binding competition experiments 
Competition of binding between HS02-52G and the NB aptamers to APC was also 
assessed using the APC OECA setting as previously described 56. In brief, increasing 
concentrations of aptamers (0-100 nM final concentration) were incubated with APC (180 
pM final concentration) for 1 h at room temperature (RT). The mixture was then 
transferred to the wells of microtiter modules primed with immobilized HS02-52G 
aptamers and incubated for 2 h at RT. After washing, the amount of APC bound to the 
immobilized HS02-52G aptamers was measured using 100 µl of 300 µM of the fluorogenic 
substrate PCa 5791 (λex = 360 nm / λem = 460 nm) in dilution buffer (10 mM Tris.HCl, 4 
mM CaCl2, 154 mM NaCl, pH 8.5) and a Synergy 2 microplate reader (Biotek, Bad 
Friedrichshall, Germany). 
 
4.3.8. APC amidolytic assay 
The influence of aptamer binding on the amidolytic activity of APC was assessed in the 96-
well format using fluorogenic and chromogenic APC peptide substrates. For fluorogenic 
measurement, increasing concentrations of aptamers (0-316 nM final concentration) 
were incubated with rAPC (180 pM final concentration) in assay buffer (10 mM Tris-HCl, 
137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 0,1% BSA, pH 7.4) in a total volume of 50 µl in 
white F8 Fluoronunc modules (Thermo Fisher Scientific [Nunc], Wiesbaden, Germany). 
For chromogenic measurement, rAPC (370 pM final concentration) was incubated with 
increasing concentrations of aptamers (0-100 nM final concentration) in standard 
transparent 96-well round-bottom plates, pre-coated with BSA (2% BSA in PBS, pH 7.4 
containing 0.05% Tween 20). Subsequently, 50 µl of PCa 5791 or p-Glu-Pro-Arg-MNA at a 
final concentration of 150 µM or 140 µM, respectively were added and substrate 
hydrolysis rates measured (chromogenic: λabs = 405 nm/fluorogenic: λex = 360 nm / λem 
= 460 nm) using the Synergy 2 microplate reader (Biotek). 
 
4.3.9. FVa and FVIIIa inactivation assays 
To determine the influence of aptamer binding on APC-mediated inactivation of FVa, 150 
pM FVa in assay buffer (20 mM Tris-HCl [pH 7.6], 137 mM NaCl, 5 mM CaCl2, 1 mg/ml BSA 
and freshly added 10 µg/ml phospholipids) was incubated with 0.25 ng/ml (4.5 pM) rAPC 
in the presence of increasing concentrations of aptamer (0-200 nM). After incubation for 
30 min, 25 µl of the mixture were transferred to a well containing 1.3 pM human FXa and 
10 mM fluorogenic thrombin substrate (Pefaflour I-1650) and supplemented to a total 
volume of 75 µl with assay buffer. Finally, 50 µl of 25 nM human prothrombin were added 
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to the reaction mixture and thrombin catalyzed substrate hydrolysis was monitored using 
Synergy 2 microplate reader and a λex 360 / λem 460 nm filter set. 
To determine the influence of aptamers binding on APC-mediated inactivation of FVIIIa a 
tenase assay was used. This assays measures the FVIIIa-activity through the rate of FXa-
formation. In Brief, activated FVIII was prepared by incubation of 1 U recombinant human 
FVIII with 0.025 U human α-thrombin in PBS buffer ([pH 7.4] 1 mg/ml BSA) in a total 
volume of 100 ml. After 2 min of incubation at room temperature, argatroban  (final 
concentration of 100 µM) was added to terminate thrombin activation. Activated FVIII at 
a concentration of 0.16 U/µl was incubated with 10 nM rAPC in assay buffer (20 mM Tris-
HCl [pH 7.6], 137 mM NaCl, 10 mg/ml phospholipids, 5 mM CaCl2, 1 mg/ml BSA) in the 
absence or presence of aptamers or controls (0.32–316 nM). After incubation for 30 min, 
25 µl of the mixtures was transferred to the wells of black F16 Fluoronunc modules 
(Thermo Fisher Scientific, Nunc) containing 3 nM human FIXa and 333 µM Boc-Ile-Glu-Gly-
Arg-AMC in a total volume of 75 µl assay buffer. Subsequently, 50 µl 25 nM human FX in 
assay buffer was added to the wells and the kinetic of FXa-mediated substrate hydrolysis 
monitored using a Synergy 2 microplate reader. 
 
4.3.10. Thrombin generation assay 
Increasing concentrations of aptamers and controls (0 – 800 nM final concentration) were 
added to pooled normal human plasma spiked with 2 U/ml rabbit thrombomdulin (TM). 
Plasma samples w/o rabbit TM and aptamers were applied as controls. Thrombin 
generation in the samples was monitored by calibrated automated thrombography (CAT) 
using standard reagents (Stago, Düsseldorf, Germany) and a Fluoroskan Ascent FL plate 
reader (Thermo Scientific) as previously described 116.  
 
4.3.11. APC anticoagulant activity in whole blood 
Whole blood clotting times were measured using aPTT reagents and the semi-automated 
10-channel ball-coagulometer KC10 (Amelung, Lemgo, Germany [now: Diasys, Flacht, 
Germany]). In brief, 100 µl of citrated whole blood containing different concentration of 
each aptamer (0.32 - 1 µM final concentration) and 50 µl of the contact phase activator 
Actin FS (Siemens Healthcare Diagnostics) were added to the system-specific cuvettes and 
incubated at 37°C for 3 min. Subsequently, 50 µl of 25 mM CaCl2 solution were added to 
start the clotting reaction. Time to detectable clot formation was measured mechanically 
and given in seconds. 
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4.3.12. APC-APC-inhibitor complex formation testing 
The inactivation rates of APC in plasma in the presence and absence of the different APC-
aptamers were assessed using a combined functional and immunological assay. In this 
assay normal human plasma was replaced by PC-deficient plasma to avoid competition 
between endogenous PC and exogenously added APC for binding to the PC antibodies. 
PC-deficient citrated plasma was spiked with argatroban and corn trypsin inhibitor (CTI) 
reaching final concentrations of 100 µM and 25 µg/ml, respectively. Subsequently, the 
plasma was recalcified (10 mM Ca2+ final concentration) using a 1 M CaCl2 stock solution. 
Primed plasma aliquotes were then spiked with aptamers or controls (100 nM final 
concentration) and sub-samples taken at the indicated time points. Each sub-sample was 
diluted 1 to 10 in D-PBS buffer containing 0.1% BSA and 22.2 µM of the APC inhibitor 
aprotinin and stored on ice. After completion of the sample series, 100 µl of the diluted 
sub-samples were incubated at RT for 1 h in the wells of microtiter-modules coated with 
the sheep anti-human PC antibody. 
White Maxisorp F8 Fluoronunc microtiter modules (Nunc) were coated with sheep anti-
human PC antibody (10 µg/ml, 100 µl/well) in coating buffer (Na2CO3 30 mM, NaHCO3 200 
mM, pH 9) at 4°C overnight. After three times of automated washing (ELx50 microplate 
washer, Biotek, Bad Friedrichshall, Germany) with D-PBS washing buffer (1x D-PBS, pH 
7.4, 0.05% Tween 20; 300 µl/ well), remaining binding sites were blocked by incubation 
with 200 µl/well blocking buffer (1x D-PBS, pH 7.4, 2 mg/ml BSA, 0.05 % Tween 20) for 2 h 
at RT. After incubation, the blocking buffer was aspirated from the wells (using the Elx50 
microplate washer) and primed microtiter-modules sealed and stored at 4°C until used.   
After washing, the residual activity of the immobilized APC was monitored using a 
fluorogenic peptide substrate (300 µM) in substrate buffer (100 µl/well). Substrate 
hydrolysis was monitored at 360ex/460em nm by kinetic measurement for 2 h using the 
Synergy 2 microplate reader (Biotek). Thereafter, a HRP-conjugated goat anti-human PCI 
antibody (0,5 µg/ml; 100 µl/well) was added to the wells and incubated for 1h at RT. 
Subsequent to washing, in order to assess the amount of APC-PCI complexes captured in 
the wells, BM chemiluminescence substrate (Roche) was added (100 μl/well) and 
luminescence intensity measured at 460 nm using the Synergy 2 microplate reader.  
 
4.4. Supplementary tables and figures 
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Table S 4.1. Aptamer sequences identified by cloning / sanger sequencing of two distinct selection 























Table S 4.2. Binding affinities of full length aptamers, truncated variants and HS02-52G to 
recombinant APC, plasma derived Protein C, as well as the structurally similar serine proteases 
plasma derived thrombin and recombinant activated factor VII. 
Aptamer  rAPC pPC pFIIa rFVIIa 
NB1-83 20.24 n.b. n.b. n.b. 
NB1-46 1.27 n.b. n.b. n.b. 
NB2-81 1.57 n.b. n.b. n.b. 
NB2-57 0.95 n.b. n.b. n.b. 
NB2-57G 0.79 n.b. n.b. n.b. 
NB2-51 4.72 n.b. n.b. n.b. 
NB3-82 0.17 n.b. n.b. n.b. 
NB3-49 0.05 n.b. ˃ 1 µM n.b. 
NB3-47 0.07 ˃ 1 µM n.b. n.b. 
NB3-49C 0.87 n.b. n.b. n.b. 
NB3-49CC 0.01 n.b. ˃ 1 µM ˃ 0.1 µM 
HS02-52G 0.68 ˃ 1 µM ˃ 1 µM n.b. 
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Table  S 4.3. Half maximal inhibitory concentrations (IC50) of full length and truncated APC 














 [Fig. S 4.4 A] 
Competition 
experiment  using 
HS02-52G (OECA 
assay)  




[Fig. S 4.4 C] 
NB1-83 20.24 138.7 4.18 6194 
NB1-46 1.27 166.5 3.2 7581 
NB2-81 1.47 144.4 10.92 1843 
NB2-57G 4.48 129.1 13.10 996 
NB3-82 0.17 180.1 5.98 5548 
NB3-49 0.05 115.3 6.35 9838 




















assay    










NB1-83 1.74 1.83 6.63 14.38 627.6 
NB1-46 1.31 0.86 5.93 11.22 n.b. 
NB2-81 3.54 3.03 6.96 38.48 n.b. 
NB2-57G 2.47 2.87 90.85 43.01 n.b. 
NB3-82 0.86 4.37 11.64 13.12 150.8 
NB3-49 1.16 0.90 13.53 8.26 46.56 
HS02-52G 0.36 0.32 1.52 4.91 35.65 
n.b., no binding. Values are given as means of two measurement. 
 




Figure S 4.1. Monitoring of CE-SELEX by next generation sequencing. The evolution profiles of the 
most abundant sequences identified from (A) IHT1-based selection and (B) IHT2N-based selection. 
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Figure S 4.2. In-silico-prediction of secondary structures and key characteristics of full-length and 
truncated variants of NB1 (A), NB2 (B), and NB3 (C) extracted from m-fold web server on 
17.09.2015. In each group, the numbering follows the same order as full-length aptamer. The 
consensus sequence highlighted in gray. Each circle or quadrangle represents the corporation of 
the intended nucleotide in a bulge and G-quadruplex forming motif, respectively. Addition of 
complementary nucleotides was specified with * while nucleotides replaced by a complementary 
nucleotide (according to the Watson-Crick base pairing) marked with †. Dissociation constant (Kd) 
is shown in nM. 




Figure S 4.3. G-quadruplex analysis. (A) Non-denaturing polyacrylamide gel electrophoresis (20% 
acrylamide gel supplemented with 50 mM KCl) for G-quadruplex structure detection using 
SybrGreen (1x) staining or (B) Thioflavin T (1 µM) staining. (C) The fluorescence enhancement 
resulting from polyacrylamide gel electrophoresis stained by Thioflavin T. The intensity of the 
45Ag band used as positive control was considered for intensity normalization. (D) Fluorescence 
enhancement of SybrGreen (1x) and Thioflavin T (1 µM) incubated with NB aptamers and related 
truncated variants. Error bars correspond to standard deviation of three measurements.  




Figure S 4.4. Binding competition experiment. (A) Increasing concentrations of NB aptamers were 
incubated with rAPC at a final concentration of 20 nM followed by addition of radioactively 
labeled HS02-52G as the competitor. The reaction mixture passed through nitrocellulose 
membranes and remaining radioactivity was quantified. (B) NB aptamers as competitors were 
incubated with rAPC at a final concentration of 180 pM followed by transfering the mixture to the 
wells primed with immobilized HS02-52G aptamers. Residual amount of APC after washing was 
measured using an APC-specific fluorogenic substrate. Reduced APC amidolytic activity is an 
indicator of the replacement of NB aptamers by capturing ligand, HS02-52G. (C) Increasing 
concentrations of unfractionated heparin (UFH) were incubated with rAPC (20 nM final 
concentration) followed by addition of radioactively labeled NB aptamers. The reaction mixture 
passed through nitrocellulose membranes and remaining radioactivity was quantified. The 
intensity in the wells without competitor was defined as 100% value. Values are given as means of 
two measurements. 
 




Figure S 4.5.  Influence of APC-aptamers and truncated variants on APC amidolytic activity. 
Recombinant APC (180 pM) was incubated with increasing concentrations of APC-aptamers  and 
cleavage rates of the (A) fluorogenic peptide substrate (Pyr-Pro-Arg-AMC) at a final concentration 
of 150 µM or the (B) chromogenic peptide substrate (p-Glu-Pro-Arg-MNA) at a final concentration 
of 140 µM measured. HS02-52G and AD02-52 were used as positive and negative controls, 
respectively. Data are shown as means of duplicates. 
 
Figure S 4.6. The impact of increasing concentrations of the full-length NB aptamers and 
truncated variants on APC-mediated inactivation of FVa. Purified factor Va (150 pM final 
concentration) was incubated with 4.5 pM rAPC in the presence of NB aptamers. Thrombin 
catalyzed substrate hydrolysis was monitored in the prothrombinase/tenase assay. Aptamers 
HS02-52G and AD02-52 have been used as positive and negative controls, respectively. All results 
are shown as means of duplicates. 
 




Figure S 4.7. The impact of increasing concentrations of the full-length NB aptamers and 
truncated variants on APC-mediated inactivation of FVIIIa.Thrombin activated FVIII (0.16 U/ml) 
was incubated with APC (10 nM) in the presence of different concentration of aptamers or 
nagative control, AD02-52G. FXa-catalyzed substrate conversion was monitored after addition of 
FIXa and FX in final concentration of  2 nM and 8.3 nM, respectively. 
 
Figure S 4.8. Influence of APC aptamers and truncated variants on inhibition of APC by PCI. (A) 
Recombinant APC (final concentration of 1.9 nM) was spiked to PC-deficient plasma in the 
presence of 100 nM NB aptamers followed by sub-sampling and capturing of APC using sheep 
anti-human PC antibody primed plates. Residual activity of APC was measured through 
fluorogenic peptide substrate conversion. (B) Subsequently, a HRP-conjugated goat anti-human 
PCI antibody was added to the wells and APC-PCI complex formation was monitord using BM 
chemiluminescence substrate. The luminescence intensity corresponds to the time point of 120 
min incubation of HS02-52G aptamer was considered as 100% value. Aptamers HS02-52G and 
AD02-52 have been used as positive and negative controls, respectively. Results are shown as 
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